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Introduction: We studied the evolution of sensory neuropathy after antiretroviral therapy (ART) in 
human immunodeficiency virus–infected South Africans.  
 
Methods: Enrolment commenced before ART with 6-monthly follow-ups for 24 months. Symptomatic 
distal sensory polyneuropathy (SDSP) was defined as one symptom and sign. Symptom/sign scores 
were compared between visits. 
 
Results: We enrolled 184 participants. Pre-ART, 16% had SDSP. After 18 months of ART, pain 
prevalence decreased in those with pre-ART SDSP (odds ratio [OR], 0.09; 95% confidence interval 
[95%CI], 0.03-0.29). Symptoms improved in 50% ever experiencing pain (mean improvement=-4.5 on 
11-point scale). Participants SDSP-free pre-ART developed SDSP at a rate of 18 per 100 person-
years. After 24 months, 18% had SDSP. Stavudine (60% of cohort) did not predict incident SDSP, but 
associated with increased prevalence of reduced/absent reflexes at 18 months (OR, 2.24; 95% CI, 
1.08-4.65).  
 
Conclusions: Painful symptoms improved during ART. Evolving sensory neuropathy was due to 
increasing small and large fiber dysfunction. 
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ABSTRACT: Introduction: We studied the evolution of sen-
sory neuropathy after antiretroviral therapy (ART) in human
immunodeficiency virus–infected South Africans. Methods:
Enrolment commenced before ART with 6-monthly follow-ups
for 24 months. Symptomatic distal sensory polyneuropathy
(SDSP) was defined as one symptom and sign. Symptom/sign
scores were compared between visits. Results: We enrolled
184 participants. Pre-ART, 16% had SDSP. After 18 months of
ART, pain prevalence decreased in those with pre-ART SDSP
(odds ratio [OR], 0.09; 95% confidence interval [95%CI], 0.03-
0.29). Symptoms improved in 50% ever experiencing pain
(mean improvement 5 4.5 on 11-point scale). Participants
SDSP-free pre-ART developed SDSP at a rate of 18 per 100
person-years. After 24 months (n 5 102), 18% had SDSP. Stav-
udine (60% of cohort) did not predict incident SDSP, but associ-
ated with increased prevalence of reduced/absent reflexes at 18
months (OR, 2.24; 95% CI, 1.08-4.65). Discussion: Painful
symptoms improved during ART. Evolving sensory neuropathy
was due to increasing small and large fiber dysfunction.
Muscle Nerve 57: 371–379, 2018
Sensory neuropathy, comprising painful symptom-
atic distal sensory polyneuropathy (SDSP) and asymp-
tomatic distal sensory polyneuropathy (ADSP), is a
frequent manifestation of human immunodeficiency
virus (HIV) infection. Sensory neuropathy has a mul-
tifactorial pathogenesis, affecting both small and
large sensory fibers.1,2 SDSP manifests as distal length-
dependent and symmetrical neuropathic symptoms
of numbness, paresthesia, and/or burning pain. Pain-
ful SDSP is noted in patients with advanced HIV
infection, or coincident with symptoms of concomi-
tant tuberculosis (TB) infection, either before or
more commonly soon after initiation of TB treat-
ment,3 or within the first 3–6 months of antiretroviral
therapy (ART). Incident SDSP within the first 6
months of ART occurs particularly in those treated
with dideoxynucleotide reverse transcriptase inhibi-
tors (e.g., stavudine) and/or with a greater CD4 1 cell
recovery.4–7 While ADSP is prevalent among individu-
als before starting ART, the prevalence of ADSP
increases over time post-ART initiation.8,9
Research has focused on identifying factors that
predict sensory neuropathy risk; however, fewer stud-
ies have prospectively and longitudinally followed
patients from before initiation of ART. Therefore, the
evolution and recovery of established neuropathic
symptoms and signs during ART is not well described.
Evans et al. (2011) followed a study cohort prospec-
tively but these participants entered the study at varied
times after starting ART.8 Another prospective cohort
from sub-Saharan Africa followed participants for 6
months after ART initiation and reported the resolu-
tion of neuropathic symptoms in 22% and signs in
23%.10
This study describes the evolution of sensory
neuropathy during the first 2 years of ART in a
community-based cohort of black South Africans
enrolled in a government-run HIV treatment pro-
gram. We focused on the response of pre-existing
HIV-associated SDSP to ART initiation, the inci-
dence of SDSP after ART initiation, comparing
stavudine versus non–stavudine-containing regi-
mens and other risk factors, and the temporal evo-
lution of sensory symptoms and signs.
PATIENTS AND METHODS
Study Design, Setting, and Population. Over a 1.5-year
period HIV-infected patients scheduled to commence ART
within the following 7 days were recruited from the HIV
clinic at Crossroads Community Health Centre in Cape
Town, South Africa. Patients attend this clinic on an outpa-
tient basis and are, therefore, generally medically stable.
The primary demographic is black, predominantly Xhosa-
speaking South Africans.
Participants were eligible if 18 years, had confirmed
HIV infection, and met criteria for ART initiation in the
Additional supporting information may be found in the online version of
this article
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antiretroviral therapy; BPNS, brief peripheral neuropathy screen; CI, confi-
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government-run HIV treatment program (before May 2010:
CD4 1 cell count 200; after May 2010: CD4 1 cell count
 350 cells/mm3). Study entry exclusion criteria were known
diabetes mellitus, serious systemic illness, severe diarrhea, co-
morbid neurological disease, TB treatment initiated within
the preceding 2 months, exposure to glucocorticoids within
the preceding 6 months, and pregnancy.
The University of Cape Town Research Ethics Commit-
tee approved this prospective longitudinal cohort study. Par-
ticipants provided written informed consent to participate.
Participant Assessment. Participants were examined
before the initiation of ART (referred to as baseline), and
3, 6, 12, 18 and 24 months thereafter, or until loss to
follow-up. At each visit, participants underwent a basic
examination including resting blood pressure, focused neu-
ropathy examination, anthropometrical assessments, and
metabolic analyses (fasting glucose, insulin, cholesterol, tri-
glycerides, low density lipoprotein, and high density lipopro-
tein). Clinical, medication, and alcohol use history and
other laboratory data were obtained from chart review and
participant interview. Alcohol use was defined as any alcohol
intake during the previous year.2 Laboratory data obtained
from chart review consisted of baseline creatinine, alanine
transferase, hemoglobin, white cell count, baseline/pre-ART
and 24-week CD4 1 cell count, and 24-week viral load (base-
line viral loads were not routinely performed in South Afri-
can government-run HIV programs).
The focused neuropathy examination was performed by
one of four clinicians (C.M.C., J.J.v.d.W., J.-R.V., and
J.M.H.) using the Brief Peripheral Neuropathy Screen
(BPNS)11 and a reduced version of the Total Neuropathy
Score (TNSr) as previously described.2 Worst pain, paresthe-
sia, and numbness symptom severity were subjectively
assessed on a visual numerical rating scale (NRS) from 0 to
10 using a Xhosa-translated symptom questionnaire as part
of the BPNS tool.2 The anatomical extent of symptoms (any
of pain, paresthesia, or numbness) were also scored accord-
ing to the TNSr and included no abnormality (0), involve-
ment of the toes and/or soles of feet only (1), extending to
the ankles (2), knees (3), and extending above the knees
and/or including hands (4). The neuropathy examination
included assessments of vibratory and pinprick sensation,
and tendon reflexes as part of the BPNS and TNSr. The
anatomical extent of vibration and pinprick sensation
impairment was scored from 0 to 4 according to the TNSr
as for symptoms above. Reflexes were scored as normal (0),
reduced ankle jerks (1), absent ankle jerks (2), absent ankle
jerks and others reduced (3), and all reflexes absent (4). In
addition, position sensation was evaluated at the big toe
and abnormal position sensation defined as >20% mistakes
(out of 10 trials). All abnormal scores required bilateral
symmetrical involvement.
Definitions. The diagnosis of SDSP required the presence
of 1 sensory symptom (pain, paresthesia or numbness)
with 1 neuropathic sign (impaired vibration sensation,
impaired pinprick sensation, or reduced/absent reflexes).
ADSP was defined by the presence of 1 neuropathic sign
in the absence of sensory symptoms. Incident SDSP was
defined as no symptoms at baseline with development of
SDSP after ART initiation. Worsening symptoms were
denoted by at least 2-point increase in NRS, whereas
improvement was denoted by at least 2-point decrease in
NRS.12 At least 1-point change in TNSr denoted either
worsening or improvement of sensory symptoms and neuro-
pathic signs.
Statistical Analysis. Stata 12.0 (StataCorp. College Sta-
tion, Texas) was used for the statistical analysis. The partici-
pant characteristics and neuropathy scores at baseline (pre-
ART) and at 24 months were described by proportions or
medians with interquartile range (IQR). Differences
between the SDSP group and SDSP-free group were com-
pared using the chi-square test and Wilcoxon rank-sum test.
Multiple logistic regression predicted baseline SDSP in a
model that included the significant risk factors (P< 0.05) of
participant age (per unit increase), previous/current TB,
waist:hip ratio (per 0.01 unit increase), and triglyceride lev-
els (per 0.1 unit increase). An odds ratio (OR) and 95%
confidence interval (CI) was estimated for each covariate.
A multivariate Cox-proportional hazards regression
model was used to predict onset of incident SDSP in partici-
pants who were SDSP-free at baseline, and used age 40
and fasting insulin as covariates. Data were assumed to be
uninformatively censored. The hazard ratio (HR) and 95%
CI are presented. The magnitude of symptom NRS and
TNSr improvement/worsening over time was estimated by
the mean score difference (with standard errors) between 2
visits (from the first observation of the abnormality until the
last observation) for each symptom and sign in all partici-
pants ever experiencing the abnormality.
Population average logistic regression models, assuming
an exchangeable within-subject correlation structure, were
used to model the prevalence of symptoms and signs at
each visit. Prevalence was compared with baseline in the
whole cohort, and then in and between groups. Model A
compared the group that entered the study with SDSP ver-
sus the group that entered the study SDSP-free; and Model
B compared the group that received a stavudine-containing
regimen versus a non–stavudine-containing regimen. As a
result of nonmonotonic nonlinear time profiles, time was
treated as a categorical variable and modeled as a dummy
variable that compared prevalence at follow-up visits to that
at baseline. The model was plotted and estimated ORs and
95% CIs reported. Because of missing data, the 24-month
visit was excluded from the analysis and models were
repeated on imputed data; results for the analysis done on
the imputed data supported the analysis done on the unim-
puted data.
RESULTS
Baseline Characteristics. One hundred and ninety
patients were enrolled in the study. Two partici-
pants were excluded as they did not commence
ART within 2 weeks of the baseline (pre-ART)
assessment. One participant was excluded because
of asymmetrical neuropathic signs on examination
and three withdrew consent. The baseline study
sample, therefore, comprised 184 participants.
The baseline assessment was performed a
median of 1 day before initiation of ART (IQR 1–
5). The study population was predominantly
women (70%), with a median age of 33 years
(Table 1, Supplementary Table S1, which is avail-
able online). Overall, 38% had a history of previ-
ous or current TB treatment; 57% of this group
had completed TB treatment before study entry,
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Table 1. Baseline (pre-antiretroviral therapy) and 24-month clinical and laboratory characteristics by SDSP status.*
Baseline 24-month
Characteristic Total n 5 184 SDSP n 5 30 SDSP-free n 5 154 P-Value Total n 5 102 SDSP n 5 18 SDSP-free n 5 84 P-Value
Women, n (%) 130 (70.3) 20 (66.7) 110 (71.0) 0.64 72 (70.6) 11 (61.1) 61 (72.6) 0.33
Age,‡ years 33 (26–39) 37 (26–44) 32 (26–37) 0.013 35 (29–42) 39.5 (32–47) 33.5 (28.5–39.5) 0.030
Height‡, cm 161 (156–167) 162 (155–168) 161 (156–167) 0.64 161 (156–167) 162 (155–168) 161 (156–167) 0.67
Body mass index,‡ kg/m2 23.3 (20.4–27.7) 23.7 (21.0–25.9) 23.2 (20.4–27.8) 0.60 26.7 (21.7–32.7) 25.6 (21.5–32.0) 26.7 (21.9–32.7) 0.85
Waist:hip ratio‡ 0.86 (0.81–0.90) 0.88 (0.84–0.93) 0.85 (0.81–0.90) 0.010 0.86 (0.82–0.92) 0.90 (0.85–0.94) 0.86 (0.81–0.90) 0.10
Previous TB, n (%) 69 (37.3) 51 (73.9) 51 (32.9) 0.005 39 (38.6) 7 (38.9) 32 (38.6) 0.98
Current TB, n (%) 29 (15.7) 9 (30.0) 20 (12.9) 0.018 0 (0) 0 (0) 0 (0)
Alcohol use, n (%) 51 (28.7) 6 (20.7) 45 (30.2) 0.30 ND
CD4 1 count,‡ cells/mm3 156 (113–195) 156 (105–217) 157 (114–194) 0.56 ND
CD4 1 count200, n (%) 138 (77.1) 21 (72.4) 117 (78.0) 0.51 ND
Fasting glucose,‡ mmol/L 4.7 (4.4–4.9) 4.7 (4.5–4.9) 4.6 (4.4–4.9) 0.56 4.7 (4.4–5.0) 4.6 (4.3–5.2) 4.7 (4.4–5.0) 0.98
OGTT (120 min),‡ mmol/L 5.3 (4.6–6.1) 5.5 (4.6–6.7) 5.2 (4.6–6.1) 0.17 5.2 (4.4–5.9) 5.5 (5.1–6.7) 5.0 (4.3–5.7) 0.004
Impaired OGTT, n (%) 15 (9.1) 3 (11.1) 12 (8.6) 0.58 9 (11.0) 3 (20.0) 6 (9.0) 0.22
Fasting insulin,‡ mIU/L 5.3 (2.5–8.6) 4.3 (2.7–9.0) 5.5 (2.5–8.6) 0.24 5.0 (2.8–8.9) 3.7 (1.5–10.5) 5.2 (3.3–8.5) 0.45
HOMA–IR‡ 1.1 (0.5–1.8) 0.9 (0.5–1.9) 1.15 (0.5–1.8) 0.26 1.0 (0.5–1.9) 0.6 (0.3–2.1) 1.1 (0.6–1.8) 0.50
Triglycerides,‡ mmol/L 0.9 (0.7–1.2) 1.0 (0.8–1.4) 0.8 (0.6–1.0) 0.015 0.8 (0.7–1.2) 0.8 (0.7–1.2) 0.9 (0.7–1.2) 0.71
*SDSP, symptomatic distal sensory polyneuropathy; OGTT, oral glucose tolerance test; HOMA-IR, homeostatic model assessment of insulin resistance; ND, no data.








































while 43% were receiving treatment at study entry.
Only seven of those on TB therapy (23%) were
receiving 25 mg vitamin B6 supplementation. The
median CD4 1 cell count was 156 cells/mm3. At
study entry, almost all participants ( 95%) were
also receiving cotrimoxazole and vitamin B-
complex supplements.
Follow-up Characteristics. Among the 184 partici-
pants who were examined at baseline (pre-ART),
160 (86%) had at least one follow-up assessment
and 102 (55%) completed 24 months of follow-up.
The median attrition rate per visit was 12%. Partici-
pants who were lost to follow-up did not differ sig-
nificantly from those who remained in the study
when comparing baseline characteristics and base-
line sensory neuropathy status between the two
groups (data not shown).
Of those with follow-up data, 100 (61%) par-
ticipants began ART with a stavudine-containing
regimen, 46 (28%) with a tenofovir-containing
regimen and 18 (11%) with a zidovudine-
containing regimen. ART data are missing for 1
participant. Eight participants started TB treat-
ment after study entry. At 6 months, viral control
(viral load< 20 copies/ml) was noted in 82 par-
ticipants (86%) and CD4 1 cell counts improved
from a median of 156 (IQR, 113–195) cells/mm3
at baseline to 261 (IQR, 190–365) cells/mm3. At
24 months, less than half the cohort (48%)
remained on cotrimoxazole and vitamin B-
complex supplements with similar proportions
among those with or without SDSP (Supplemen-
tary Table S1). There were no participants on
anti-TB drugs and only two were receiving vita-
min B6 (25 mg) supplementation.
Neuropathy before ART Initiation. Before ART initia-
tion, 30 (16%) participants had SDSP and 73
(39%) had ADSP. Table 1 and Supplementary
Table S1 compare the clinical and laboratory char-
acteristics between baseline (pre-ART) SDSP and
SDSP-free groups. Significant associations were
age, waist:hip ratio, previous and current TB treat-
ment, and higher triglyceride levels. Risk factors
independently associated with baseline SDSP were
previous or current TB treatment (adjusted OR,
5.4; 95% CI, 1.9-15.2) and higher triglyceride levels
(OR, 5 1.1 per 0.1 unit increase, 95% CI, 1.0-1.3).
No baseline characteristics showed a significant
association with ADSP (data not shown).
In participants with pre-ART SDSP, pain and
paresthesia were present in 83%; pain was reported
to be moderate-to-severe (NRS 4) in 76% of
those with pain (Supplementary Table S2).
Impaired pinprick sensation was more frequent in
SDSP observations than in ADSP observations
(83% vs. 33%; P< 0.001). In 30% of SDSP
observations, abnormal pinprick sensation was the
only abnormal sign elicited. Impaired vibration
sensation was also more frequent in the SDSP
group than in the ADSP group (P 5 0.015).
Altered position sense in the toes was evident in
17 (9%) and similar in those with or without neu-
ropathic symptoms. Before ART initiation, 7 (4%)
participants had neuropathic symptoms in the
absence of neuropathic signs.
Incident Symptomatic DSP after ART Initiation and
Risk Factors. In participants who were SDSP-free
at baseline, incident SDSP occurred at a rate of
17.8 per 100 person-years; 95% CI, 12.7-25.1), with
a higher rate of incident SDSP during the first 6
months (46.0 per 100 person-years; 95% CI, 30.9-
69.9). Incident SDSP was associated with age 40
years (HR, 3.0, 95% CI, 1.5-6.1) and inversely asso-
ciated with fasting insulin levels (HR, 0.8; 95% CI,
0.6-1.0). On multivariate analysis, the association
with fasting insulin remained significant (adjusted
HR, 0.8; 95% CI, 0.6-1.0), but the association with
age did not. Use of stavudine also did not signifi-
cantly predict onset of SDSP (HR, 1.4; 95% CI,
0.7-2.7), nor did ADSP at baseline (HR, 1.6; 95%
CI, 0.8-3.2).
Of the 102 participants remaining in the study
at the 24-month evaluation, 18 (18%) had SDSP
and 63 (62%) ADSP (Table 1 and Supplementary
Table S1). At this final visit, SDSP was associated
with older age and higher glucose levels after the
oral glucose tolerance test. In contrast to the base-
line (pre-ART) association, the fasting triglyceride
levels were similar between the SDSP and SDSP-
free group.
Evolution of Neuropathic Symptoms and Signs. Indi-
vidual neuropathic scores (NRS for symptoms,
TNSr for symptoms and signs) were evaluated lon-
gitudinally from the first observation of an abnor-
mality until censoring (Table 2). Pain scores
showed improvement in over 50% of participants
ever experiencing pain; the mean improvement in
the NRS (among those who did improve their
scores) was 4.5 and the mean improvement in
TNSr was 1.6. Only a minority (9%) experienced
worsening of pain. Improvement in pinprick and
vibration sensation scores was noted in 37% and
40%, respectively, while fewer (29%) showed
improvement in reflexes. Abnormal position sensa-
tion at the distal toes was detected in two cases
with ADSP (2%) by 24 months.
The prevalence of symptoms and signs at
follow-up visits was compared with baseline (pre-
ART) prevalence in the overall cohort (Fig. 1;
Table 3). The prevalence of symptoms remained
statistically unchanged throughout the study, aside
from an isolated increase at the 3-month visit for
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paresthesia and numbness. In contrast, the preva-
lence of signs was higher at almost all follow-up vis-
its. The prevalence of symptom and sign at follow-
up visits was compared with baseline prevalence in
and between groups: (A) group that entered the
study with SDSP versus group that entered the
study SDSP-free; and (B) group initiated on a
stavudine-containing regimen versus group initi-
ated on a non–stavudine-containing regimen. In
analysis A, the prevalence of pain and paresthesia
was noted to decrease at each follow-up visit in the
baseline SDSP group (month 18 vs. month 0; OR,
0.09; 95% CI, 0.03-0.29), while symptom preva-
lence increased in the SDSP-free group (Fig. 2A;
Supplementary Table S3). The prevalence profiles
for symptoms differed significantly between the
two groups at all follow-up visits. Prevalence of
signs increased significantly in the baseline SDSP-
FIGURE 1. Modeled prevalence of neuropathic symptoms and signs at each visit over 18 months. *Significant difference in prevalence
between indicated visit and baseline (pre-ART) visit. Refer to Table 2 for estimated ORs and 95% CIs.


















Pain 58 (31.4) 9 (15.5) 13 (22.4) 31 (53.5) 24.5 (0.4) 5 (8.6) 3.4 (0.4)
Paresthesia 59 (31.9) 12 (20.3) 9 (17.0) 32 (54.2) 25.2 (0.4) 5 (8.8) 2.4 (0.4)
Numbness 51 (27.6) 6 (11.8) 7 (13.7) 31 (60.8) 24.9 (0.5) 7 (13.3) 2.9 (0.3)
Symptoms (TNSr†) 75 (40.5) 16 (21.3) 13 (17.3) 38 (50.7) 21.6 (0.1) 8 (10.7) 1.5 (0.2)
Signs (TNSr†)
Pinprick 108 (58.4) 19 (17.6) 20 (18.5) 40 (37.0) 21.8 (0.1) 29 (26.9) 1.2 (0.1)
Vibration 77 (41.6) 14 (18.2) 20 (26.0) 31 (40.2) 21.9 (0.2) 12 (15.6) 1.6 (0.2)
Reflexes 133 (71.9) 20 (15.1) 43 (32.3) 38 (28.6) 21.1 (0.1) 32 (24.1) 1.5 (0.1)
*From the BPNS.11
†See Reference 2.
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free group, while prevalence of signs in the base-
line SDSP group remained relatively statistically
unchanged, aside for an initial drop in prevalence
at 3 months for abnormal pinprick sensation and
an increase at 6 months for reduced/absent
reflexes. Overall, the profiles for abnormal pin-
prick sensation differed significantly between the
baseline SDSP versus SDSP-free groups at all
follow-up visits.
In analysis B, participants who received stavu-
dine had a higher baseline prevalence of pain
compared with those who were started on a non–
stavudine-containing regimen (Fig. 2B; Supplemen-
tary Table S4). These patients also had lower
CD4 1 cell counts, because the government-
sponsored ART program enrolled participants with
lower CD4 1 cell counts [200/mm3] while stavu-
dine was in use, whereas the switch to tenofovir co-
occurred with starting ART when CD4 1 cell
counts were higher [350/mm3]. Nevertheless,
symptom prevalence did not differ significantly
between the two groups thereafter. Both groups
experienced an increasing prevalence of signs, but
the increase in prevalence for reduced/absent
reflexes was significantly greater in the stavudine
group for months 6, 12 and 18 (OR, 2.24; 95% CI,
1.08-4.65 for stavudine vs. non-stavudine at 18-
months). An analysis comparing the group with
baseline CD4 1 cell count 200/mm3 versus the
group with CD4 1 cell count> 200/mm3 did not
demonstrate the same effects (data not shown).
In an exploratory analysis, we compared partici-
pants who entered the study with ADSP to those
who entered the study free of both ADSP and SDSP
(Supplementary Fig. S1). This analysis showed a
trend for a higher proportion of the ADSP group
to have painful symptoms at follow-up at visits when
compared with those free of both ADSP and SDSP
pre-ART. However, the survival analysis did not
significantly support this observation.
DISCUSSION
We found SDSP in 16% and ADSP in 39% of
ART-na€ıve patients immediately before starting
ART, suggesting a substantial background preva-
lence of pre-existing HIV-associated sensory neu-
ropathy. Pre-ART SDSP was independently
associated with current or previous TB / TB treat-
ment and higher fasting triglyceride levels.
Although older age is frequently identified as a
risk factor for HIV-associated DSP, it did not
remain associated with SDSP in a multivariate anal-
ysis. We and others have found a high prevalence
of sensory neuropathy in HIV/TB co-infected
patients in similar settings.3,13 Earlier initiation of
ART may reduce the high prevalence of sensory
neuropathy demonstrated in this study by reducing
exposure to HIV-induced oxidative stress6 and co-
infection with TB. It is worth mentioning that only
a minority of participants enrolled in this study
were prescribed supplementary vitamin B6 by the
clinic during TB treatment.7 Supplementation with
vitamin B6 has been shown to prevent the sensory
neuropathy associated with isoniazid.14 Although
vitamin B12 deficiency has been reported in 10%
in a similar population,15 we found macrocytic ane-
mia (a proxy for vitamin B12 deficiency) in only
three participants at baseline.
There were some “metabolic” signals which
associated with SDSP in this black, relatively young
African cohort (which characteristically comprises
predominantly women).1,2 We replicated our previ-
ous observations that higher waist:hip ratios (uni-
variate analysis) and fasting triglycerides levels
associated with SDSP pre-ART.2 Although the latter
association has been observed in an ART-treated
cohort,16 we did not demonstrate higher fasting
triglyceride levels in SDSP after 24 months of ART.
It is unclear whether the substantially lower level
of absolute fasting triglycerides in our African
cohort compared with nonfasting results from first-
world cohorts16,17 is due to the timing of the blood
draws, or whether it suggests the absolute triglycer-
ide level is not itself critical, but rather a surrogate
biomarker for painful neuropathy. The latter
explanation is supported by the plateau in preva-
lence of painful SDSP after 6 months of ART
Table 3. Comparison of symptom and sign prevalence (odds ratios) between baseline (pre-antiretroviral therapy) and follow-up visits.*
Month 3 vs. 0
OR (95% CI)
Month 6 vs. 0
OR (95% CI)
Month 12 vs. 0
OR (95% CI)
Month 18 vs. 0
OR (95% CI)
Symptoms
Pain 1.31 (0.86–2.00) 1.05 (0.66–1.65) 0.89 (0.55–1.46) 1.00 (0.60–1.66)
Paresthesia 1.62 (1.07–2.47) 1.01 (0.64–1.62) 0.91 (0.56–1.50) 0.18 (0.60–1.67)
Numbness 1.68 (1.07–2.64) 1.42 (0.88–2.30) 1.40 (0.85–2.32) 1.53 (0.91–2.56)
Signs
Pinprick 1.10 (0.78–1.56) 1.65 (1.16–2.33) 1.85 (1.29–2.66) 2.14 (1.47–3.12)
Vibration 2.13 (1.37–3.34) 2.68 (1.71–4.20) 2.54 (1.60–4.05) 3.25 (2.02–5.22)
Reflexes 1.90 (1.38–2.61) 2.50 (1.80–3.49) 3.14 (2.21–4.45) 2.60 (1.80–3.74)
*Bolded data denote statistical significance
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coupled with the loss of the association signal
between SDSP and fasting triglycerides at 24
months.
Our results confirm that patients are most at
risk of developing SDSP either before or within
the first 3 to 6 months of initiating ART.4,6
FIGURE 2. Modeled prevalence of neuropathic symptoms and signs at each visit over 18 months in and between groups: group that
entered the study with baseline (pre-ART) SDSP (“1”) and group that entered the study free of SDSP (“0”) (A); and group that
received a stavudine-containing regimen (“1”) and group that received a non–stavudine-containing regimen (“0”) (B). *Significant differ-
ence in prevalence between indicated visit and baseline visit. **Significant difference in prevalence profile between groups at indicated
visit. Refer to Supplementary Tables S3 and S4 for estimated ORs and 95% CIs.
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Incident SDSP (in those SDSP-free at study entry)
occurred at a higher rate during the first 6 months
(46 per 100 person-years) compared with the over-
all study period (18 per 100 person-years). The
onset of SDSP coincided with the time window in
which a potentiation of dysregulated systemic
inflammatory signals has been observed after ART
initiation, irrespective of the pre-ART CD4 1 cell
count.6,18 Incident SDSP was inversely associated
with fasting insulin. Insulin has been shown to
exert a regenerative effect and improve mitochon-
drial function in vitro.19,20 Noninsulin glucose-
lowering drugs have also been shown to have a
neuro-protective effect in HIV-associated sensory
neuropathy.21 It is noteworthy that our patients
had not received statins or hypoglycemic medica-
tions. Intriguingly, patients with painful SDSP do
not respond to standard symptomatic therapies
that provide relief in similarly painful diabetic and
other neuropathies.1,22,23 Although some symptom-
atic participants in this study received therapies for
pain (35% of symptomatic visits; mainly amitripty-
line), the study design precluded estimation of
potential benefit of these therapies.
While a small proportion (9–13%) of participants
experienced mild-to-moderate worsening of their
symptoms over time, more than half experienced a
substantial improvement in their symptoms with a
mean absolute decrease in worst pain score of 4.5
(on an 11-point scale) and a proximal regression in
anatomical extent (as measured by the 4-point TNSr
scale). Experimental models suggest that painful
symptoms are driven and maintained by exposure to
HIV proteins such as gp120 and HIV-induced
inflammatory cascades in the nerve cell body and
axon.1,24 Viral clearance and the relative stabilization
of immune dysregulation with successful ART may
potentially account for the reduction in the HIV-
associated small fiber painful neuropathic symptoms
seen in participants with pre-existing HIV-associated
SDSP. These results underscore the benefit antici-
pated from earlier ART initiation.
In contrast to the predominant improvement
in symptoms, improvement of neuropathic signs
was observed less frequently and the prevalence of
signs in the overall cohort increased significantly at
each visit. By 24 months, the proportion of partici-
pants with ADSP increased from 39% at baseline
(pre-ART) to 62%, a finding in keeping with previ-
ous reports of ADSP in long-term cohorts.8 The
accumulation of clinical evidence of nerve dysfunc-
tion may be attributed to the slow transport of dys-
functional mitochondria down axons over months
to years and the particular susceptibility of distal
sensory axons to mitochondrial defects.25,26 Of
interest, despite the increasing prevalence of neu-
ropathic signs sub-served by small (pinprick) and
larger myelinated sensory fibers (reflexes and
vibration), position sensation loss stayed low in the
first 2 years after ART initiation. It remains to be
seen whether early inflammation will impact on
subsequent mitochondrial dysfunction; however,
our data do not suggest that those with early SDSP
subsequently accumulate neuropathic signs.
The study provided a unique opportunity to pro-
spectively compare sensory neuropathy between
patients treated with a dideoxynucleotide reverse
transcriptase inhibitor (stavudine) and those treated
with other classes of antiretrovirals, as the study
coincided with the phase-out of stavudine and the
introduction of tenofovir-containing regimens in
first-line ART regimens in South Africa. The use of
stavudine did not significantly predict the onset
of SDSP, but did result in increasing prevalence of
reduced/absent reflexes compared with the non-
stavudine group. The clinical relevance of impaired
reflexes is uncertain. It should be noted that partici-
pants who were started on stavudine (as per pro-
gram guidelines) had a higher prevalence of
painful symptoms before commencing ART, possi-
bly because of lower CD4 1 cell counts seen before
the phase-out of stavudine. These patients may have
been identified using a routine symptom screen.27
During this study, none of the patients were
switched by their clinic health workers from their
initial first-line regimen.
As mentioned, abnormal pinprick sensation was
noted in a high proportion with SDSP, similar to
our previous findings2; in a third, impaired pin-
prick sensation was the only neuropathic sign eli-
cited. The BPNS, used in many studies, excludes
this easy to perform bedside test of small fiber
function, potentially missing DSP in several
patients.3 Although this modality has utility in
resource-limited settings lacking tools and exper-
tise for proper assessment of vibration sensation
and reflexes, our results suggest that the symptom-
only screening tool27 will over call SDSP in only a
small subset (4%) who had isolated neuropathic
symptoms in the absence of signs.
The study experienced loss-to-follow-up at a rate
of 12% per visit. Some loss-to-follow-up may have
been attributed to migration or limited access. An
analysis of baseline characteristics and outcomes
between patients who remained in the study and
those lost to follow-up at each visit suggested that
this loss was at random;28 however, attrition bias
cannot be excluded. We used a mixed-effect model
that accounts for loss-to-follow-up in the longitudi-
nal analysis and performed an imputed longitudinal
analysis that produced similar results to an unim-
puted analysis (data not shown).
This cohort was substantially smaller than the
multi-centered North American cohorts;8,9,21
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however, strengths of the study include prospective
longitudinal assessments from just before starting
ART, study visits at regular time intervals thereaf-
ter, and examination by the same doctors, thereby
minimizing inter-rater bias.29 In this prospective
study, we used a DSP definition of at least 1 neuro-
pathic sign as we were assessing signs from a
known baseline, which improved specificity without
having to use stricter criteria, and allows for com-
parison with other studies. All metabolic and lipid
parameters were assessed in a fasting state. A limi-
tation may be that a history of diabetes at baseline
resulted in exclusion from this study, but despite
this exclusion there was an association between
SDSP and higher glucose levels after the oral glu-
cose tolerance test after 2 years of ART. This obser-
vation requires careful attention in the follow-up
of these cases in HIV treatment programs. The rel-
atively advanced immunosuppression observed in
this study (median pre-ART CD4 1 cell count 5 156
cells/mm3), which also resulted in high propor-
tions of concomitant cotrimoxazole use at ART ini-
tiation, limits generalizability of these data to
cohorts initiating ART at higher CD4 1 cell counts.
In conclusion, we have studied the clinical evo-
lution of neuropathic symptoms and signs in a typ-
ical African community-based cohort comprising
predominantly younger women with relatively
advanced HIV-infection at the time of ART initia-
tion. Neuropathic pain largely improved in
response to ART, although a proportion developed
new painful neuropathic symptoms. Increasing
prevalence of neuropathic signs without symptoms
appeared to be related to the accrual of both small
and large fiber dysfunction.
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Supplementary Table 1.  Additional baseline (pre-antiretroviral therapy) and 24-month clinical and laboratory characteristics by symptomatic distal sensory polyneuropathy status. 

















Concomitant therapies, N (%) 
Cotrimoxazole 
Vitamin B complex* 




































Weight†, kg 62.0 (55-71) 62 (54-73) 62 (55-71) 0.95 70.1 (59.4-82) 72.6 (57.7-79.7) 68.8 (61.0-82.9) 0.86 
Systolic blood pressure†, mmHg 111 (103-121) 109 (100-119) 111 (103-121) 0.39 114 (104-123) 117 (107-127) 113 (103-123) 0.47 
Diastolic blood pressure†, 
mmHg  
72 (66-79) 70 (66-77) 73 (66-80) 0.26 73 (67-81) 77 (66-85) 73 (67-79) 0.38 
WHO HIV stage, N (%) 0.43
Stage 1 58 (32.2) 8 (27.6) 50 (33.1) ND ND ND 
Stage 2 58 (32.2) 7 (24.1) 51 (33.7) ND ND ND 
Stage 3 57 (31.7) 12 (41.4) 45 (29.8) ND ND ND 
Stage 4 7 (3.9) 2 (6.9) 5 (3.3) ND ND ND 
Total cholesterol†, mmol/L 3.7 (3.2-4.2) 3.7 (3.0 -4.3) 3.7 (3.2-4.2) 0.33 4.5 (3.8-4.9) 4.5 (4.0-5.0) 4.4 (3.8-5.00) 0.75 
HDL†, mmol/L 1.0 (0.8-1.1) 0.9 (0.8-1.1) 1.0 (0.8-1.1) 0.30 1.6 (1.2-1.8) 1.6 (1.2-1.8) 1.4 (1.2-1.8) 0.56 
LDL†, mmol/L 2.3 (1.9-2.8) 2.3 (1.8-2.7) 2.3 (1.9-2.9) 0.22 2.3 (1.9-3.0) 2.3 (2.1-3.1) 2.2 (1.9-3.0) 0.62 
Hemoglobin†, g/dL 11.8 (10.4-12.6) 11.6 (9.4-12.4) 11.8 (10.7-12.7) 0.18 ND ND ND 
SDSP, symptomatic distal sensory polyneuropathy; WHO, World Health Organization; HDL, high density lipoprotein; LDL, low density lipoprotein. *contains 2-4mg vitamin B6.14 
†Median (interquartile range) 
Supplementary Table 2. Distribution of baseline (pre-antiretroviral therapy) symptom scores (numerical rating scale) and sign scores 
(reduced Total Neuropathy Score) by symptomatic and asymptomatic distal sensory polyneuropathy status. 
ADSP n = 73 SDSP n = 30 
Symptoms, n (%)  No pain NA 5 (17) 
 Pain NA 25 (83) 
   NRS=1-3 6 (24) 
   NRS=4-7 14 (56) 
   NRS=8-10 5 (20) 
 No paresthesia NA 5 (17) 
 Paresthesia NA 25 (83) 
   NRS=1-3 11 (44) 
   NRS=4-7 9 (36) 
   NRS=8-10 5 (20) 
 No numbness NA 12 (40) 
 Numbness NA 18 (60) 
   NRS=1-3 6 (33) 
   NRS=4-7 8 (55) 
   NRS=8-10 4 (22) 
Signs, n (%)  Normal pinprick 49 (67) 5 (17) 
 Impaired pinprick 24 (33) 25 (83) 
   TNSr=1 17 (71) 12 (48) 
   TNSr=2 4 (17) 12 (48) 
   TNSr=3-4 3 (3) 1 (4) 
 Normal vibration 62 (85) 19 (63) 
 Impaired vibration 11 (15) 11 (37) 
   TNSr=1 11 (100) 6 (55) 
   TNSr=2 0 (0) 2 (18) 
   TNSr=3-4 0 (0) 3 (27) 
 Normal reflexes 26 (37) 13 (43) 
 Reduced/absent reflexes 47 (63) 17 (57) 
   TNSr=1 30 (64) 7 (41) 
   TNSr=2 11 (23) 4 (24) 
   TNSr=3-4 6 (13) 6 (35) 
ADSP asymptomatic distal sensory polyneuropathy; SDSP, symptomatic distal sensory polyneuropathy; NRS, numeral rating scale 
from BPNS; TNSr (reduced Total Neuropathy Score); NA, not applicable. 
Supplementary Table 3. Comparison of symptom and sign prevalence (odds ratios) between baseline and follow-up visits by baseline symptomatic distal sensory polyneuropathy 
(SDSP) status (baseline SDSP vs. no baseline SDSP), and comparison between the two groups at each visit. 
Pain Paresthesia Numbness Pinprick Vibration Reflexes 
Symptomatic Comparison OR 95%CI OR 95%CI OR 95%CI OR 95%CI OR 95%CI OR 95%CI 
DSP at 
baseline 
No Month 3 vs. 0 5.97 2.30 15.53 8.93 2.89 27.64 6.17 1.95 19.49 1.62 1.02 2.57 2.61 1.44 4.75 1.92 1.35 2.73 
Month 6 vs. 0 3.34 1.22 9.11 3.83 1.16 12.66 4.73 1.45 15.45 2.38 1.51 3.76 4.47 2.48 8.07 2.54 1.76 3.66 
Month 12 vs. 0 3.77 1.37 10.38 5.53 1.70 17.99 5.20 1.58 17.14 2.89 1.81 4.59 3.73 2.03 6.86 3.49 2.38 5.12 
Month 18 vs. 0 5.61 2.05 15.36 7.08 2.16 23.20 5.71 1.70 19.21 3.54 2.18 5.73 4.85 2.61 9.02 3.26 2.17 4.89 
Yes Month 3 vs. 0 0.20 0.07 0.56 0.33 0.11 1.00 0.82 0.32 2.11 0.25 0.09 0.67 1.89 0.82 4.37 2.17 0.92 5.10 
Month 6 vs. 0 0.26 0.09 0.75 0.27 0.09 0.81 0.73 0.28 1.90 0.50 0.18 1.41 0.83 0.35 2.01 2.97 1.18 7.46 
Month 12 vs. 0 0.13 0.04 0.40 0.11 0.03 0.36 0.57 0.20 1.61 0.40 0.13 1.17 1.26 0.50 3.16 2.03 0.80 5.16 
Month 18 vs. 0 0.09 0.03 0.29 0.10 0.03 0.33 0.67 0.24 1.87 0.36 0.12 1.05 1.56 0.62 3.90 0.97 0.41 2.32 
Yes vs. no Month 3 0.03 0.01 0.14 0.04 0.01 0.18 0.13 0.03 0.59 0.15 0.05 0.46 0.72 0.26 2.03 1.13 0.45 2.85 
Month 6 0.08 0.02 0.34 0.07 0.01 0.36 0.15 0.03 0.71 0.21 0.07 0.65 0.19 0.06 0.54 1.17 0.43 3.15 
Month 12 0.04 0.01 0.16 0.02 0.00 0.11 0.11 0.02 0.53 0.14 0.04 0.44 0.34 0.11 1.02 0.58 0.21 1.60 
Month 18 0.02 0.00 0.08 0.01 0.00 0.08 0.12 0.02 0.57 0.10 0.03 0.33 0.32 0.11 0.97 0.30 0.11 0.78 
Supplementary Table 4. Comparison of symptom and sign prevalence (odds ratios, OR and 95% confidence intervals (CI)) between baseline and follow-up visits by stavudine regimen 
(participants receiving stavudine vs. not receiving stavudine), and comparison between the two groups at each visit. 
  
 
Pain Paresthesia Numbness Pinprick Vibration Reflexes 
Stavudine 
regimen Comparison OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
No Month 3 vs. 0 1.65 0.73 3.70 2.01 0.94 4.31 1.24 0.51 2.99 0.98 0.54 1.78 3.71 1.53 8.98 2.20 1.33 3.65 
  Month 6 vs. 0 1.30 0.55 3.06 0.89 0.36 2.18 1.02 0.40 2.60 1.72 0.97 3.04 4.06 1.67 9.87 1.67 1.00 2.77 
  Month 12 vs. 0 1.30 0.53 3.19 0.53 0.18 1.61 1.07 0.40 2.82 1.50 0.82 2.75 3.06 1.20 7.78 1.61 0.94 2.75 
  Month 18 vs. 0 1.66 0.70 3.94 0.80 0.30 2.16 1.43 0.57 3.58 2.33 1.29 4.22 4.41 1.77 11.00 1.66 0.96 2.85 
Yes Month 3 vs. 0 1.18 0.72 1.95 1.45 0.87 2.42 1.85 1.09 3.13 1.16 0.75 1.80 1.68 0.98 2.88 1.79 1.18 2.70 
  Month 6 vs. 0 0.95 0.56 1.63 1.07 0.61 1.87 1.60 0.92 2.79 1.60 1.03 2.51 2.29 1.33 3.94 3.37 2.18 5.20 
  Month 12 vs. 0 0.76 0.42 1.36 1.08 0.60 1.92 1.54 0.86 2.75 2.09 1.32 3.30 2.41 1.38 4.21 5.10 3.19 8.15 
  Month 18 vs. 0 0.77 0.41 1.46 1.10 0.59 2.06 1.56 0.84 2.90 2.01 1.23 3.30 2.99 1.67 5.38 3.71 2.27 6.06 
Yes vs. no Month 0 2.56 1.03 6.34 1.96 0.81 4.72 1.91 0.71 5.17 1.38 0.71 2.70 2.69 0.95 7.64 0.68 0.37 1.25 
 
Month 3 0.72 0.28 1.86 0.72 0.29 1.80 1.49 0.54 4.17 1.19 0.57 2.49 0.45 0.16 1.28 0.81 0.42 1.56 
 Month 6 0.73 0.27 2.00 1.21 0.42 3.47 1.56 0.53 4.64 0.93 0.45 1.93 0.56 0.20 1.59 2.02 1.04 3.94 
  Month 12 0.58 0.20 1.70 2.02 0.58 7.08 1.45 0.47 4.48 1.39 0.65 2.97 0.79 0.27 2.34 3.17 1.56 6.45 
  Month 18 0.46 0.16 1.36 1.37 0.43 4.40 1.09 0.36 3.32 0.86 0.40 1.87 0.68 0.23 2.01 2.24 1.08 4.65 
Supplementary Figure 1. Symptoms and signs at each visit in the group that entered the study with 
baseline (pre-ART) asymptomatic distal sensory polyneuropathy (“1”) (n=73 at baseline) vs. group that 
entered the study free of sensory neuropathy (“0”) (n=81 at baseline). 
In addition to the two models presented in the main text comparing prevalence of symptoms and signs at 
follow-up to baseline in and between groups, a third model compared the group that entered the study 
with ADSP vs. the group which was sensory neuropathy-free at study entry. However, the model could 
not be adequately fitted due to a lack of observations at baseline (no symptoms in the ASDP group, no 
signs in the neuropathy-free group). We therefore explored the model for trends without testing for 
statistical significance. 
9) Reviewers’ comments and responses (Muscle & Nerve) 
  
Review of MUS-16-0945 
Reviewer 1: Comments to the Author 
This paper reports on the evolution of PN following initiation of ART in Africa. Strengths of the study 
include standardized assessments of subjects using validated instruments, before and after initiation of 
different forms of ART. Notably there is a comparison of rates of PN in those receiving d4T, a neurotoxic 
agent, and tenofovir, without PN toxicity. Only minor issues deserve comment as follows: 
1.      Median baseline CD4 is 156. This relatively advanced immunosuppressed cohort limits 
generalizability of these data to those initiating ART at higher CD4.  
 
We added comment in discussion. 
 
2.      It is notable that there is a discordance between the evolution of symptoms and signs of DSP 
following ART, with or without use of d4T. While there is generally a reduction or no change in symptoms 
in many patients, there is an increase in signs. The authors might discuss implications of these findings.  
 
Thank you for stressing this point. We have added a paragraph in the discussion. 
 
3.      The authors compare the evolution of PN in those that were SDSP positive or negative at baseline. 
The latter group presumably includes those that are PN-sign free and those with ADSP. It would be of 
interest to compare evolution of PN (onset of symptoms and/or onset or increase in signs) in those that 
are PN-sign free and those with ADSP at baseline. 
 
We attempted this analysis but the model failed because of a lack of observations at baseline (e.g. no 
pain in the ADSP group at baseline). Instead, we have presented observed frequencies without modelling 
prevalence and without presenting any statistical analysis, and this is presented in supplementary 
material. However, we found a trend towards a greater increase in symptoms prevalence over time in the 
ADSP group when compared to the DSP-free group. When observing signs, there is a trend for an initial 
increase in signs then levelling off for the DSP-free group, while the increase in the ADSP group is more 
sustained. These findings suggest that ADSP before ART might increase the odds for symptoms later, 
although the survival analysis did not support this hypothesis. The ADSP group will also acquire new 
signs over time, while DSP-free participants will acquire signs primarily within the first 6 months. 
 
We also experimented by inserting a “dummy” observation (n=1) at baseline to force the model, and 
found that the model supported some of these trends. We present these data as supplementary figure 
and refer to it in the text. 
 
Reviewer 2: Comments to the Author 
Congratulation on job well done. While the HIV patients included in the study are relatively young which 
makes monoclonal paraproteinemia unlikely, did you consider testing pre ART symptomatic neuropathy 
patients for vitamin B12 deficiency especially that these patients have a predominantly sensory 
neuropathy and can have nutritional problems.  
 
We agree that nutritional factors are an important component of the multifactorial pathogenesis of sensory 
neuropathy in this population. While low serum B12 levels (<200) have been noted in 10% in a similar 
population, serum B12 is an unreliable test and low levels have a poor positive predictive value for true 
deficiency. Patients with symptomatic neuropathy were not routinely investigated for B12 deficiency in the 
clinic and we also did not measure B12 in this study. However, we have reviewed our data, and using the 
presence of macrocytic anemia as a surrogate marker of B12 deficiency, we have established that it is 
unlikely to be a major contributing factor. At baseline (pre-ART), 35% had anemia (Hb <12.4 g/dl for men, 
<10.6 g/dl for women) and only 3 participants had macrocytic anemia (MCV <100). We did not do any 
further analysis but added comments in the results. 
 
Using less stringent criteria (Hb <13 g/dl for males, <12 g/dl for females), 38% had anemia and 6% had 
macrocytic anaemia (MCV <98.9). Using the less stringent criteria, macrocytic anemia was no more 
common in the symptomatic neuropathy group compared with the neuropathy-free group (6 vs 7%). It is 
important to note that the HIV clinicians’ society guidelines does not recommend the use of these less 
stringent criteria and particularly not at sea level (SAJHIVMED June 2012; 13; 87-104). We have not 
presented these data. 
 
Reviewer 3: Comments to the Author 
Study design 
1.      Definition of SDSP: Compared to the groups previous cross sectional study (Maritz et al. 2010) a 
less strict definition was used: instead of the presence of at least two neuropathic signs (reduced or 
absent reflexes, impaired vibration, or impaired pinprick), only one is required. An explanation why this 
was chosen, would be informative.  
 
We used more stringent criteria in the former cross-sectional study to increase confidence in finding true 
neuropathy at a single time point (improved specificity). In this prospective study we were able to improve 
confidence in the finding by assessing signs from a known baseline, which improved specificity without 
having to use the stricter criteria. The relaxed criteria would also improve sensitivity. 
 
We also aimed to improve generalizability/comparison of study findings, as most other studies use the 
less strict definition. 
 
2.      Measurement of symptoms: When patients were asked about neuropathic pain, were they asked 
about least, average or worst pain?  
 
Worst pain. Have clarified in the text. 
 
While measurement of pain intensity has been validated on a visual numerical rating scale (as cited in the 
text (Ferrar et al.)), has the measurement of numbness and paresthesia on this scale (and a 2 point 
decrease or increase on this scale as a significant change) been validated?  
 
No, we extrapolated from the pain data. However, we also present the ‘absolute’ score changes in 
parallel for all modalities. 
 
Would it be better to quantify patient reported numbness by location (up to ankle, up to foot, similar to 
quantifying exam findings) rather than on a numerical scale? 
 
At your suggestion, we have explored symptomatic worsening/improvement by anatomical extent using 
the TNSr scale. It is worth noting that the TNSr captures only a single score for symptoms (be it pain, 
paresthesia and/or numbness). Using a 1-point change in TNSr to define worsening/improvement, we 
noted a trend similar to that seen for the 11-point numerical scale for each modality, namely that a large 
proportion of those ever experiencing symptoms will improve before or at their last follow-up (50.7%) and 
a minority will worsen (10.7%). These findings suggest that most patients experience a proximal 
regression in the anatomical extent of their symptoms, rather than a distal extension. We have presented 
these data in Table 4 and in the text. 
 
3.      Laboratory testing/nutritional deficiencies: It may have been informative to have other laboratory 
parameters included, which commonly can cause neuropathy in western populations, such as TSH and 
vitamin B 12, as nutritional deficiencies may play a role in this population, specifically B12 deficiency in 
HIV patients.  
 
We unfortunately did not capture these data. However, for B12, please see our response above (reviewer 
2). 
 
4.      Assessment of vitamin use or neurotoxic medications - B6/Tb treatment: Was it assessed whether 
patients were taking B6 during current or previous Tb treatment?  
 
We did record these data for current usage; however, a very low proportion (n=2) reported using B6. 
Have added text. 
 
5. Was it assessed whether patient were exposed to other neurotoxic medications such as 
metronidazole? 
 
Folder reviews were completed and we did attempt to capture all concomitant medications. We have 
added this in the discussion 
 
6.      How was alcohol use defined? 
 
We used a single question screen that defined alcohol use as any intake during the preceding 1-year 
period similar to our previous cross-sectional study by Maritz et al. (2010) in which we also did not find 
alcohol to be a risk factor. We concede that the definition is probably over-inclusive; however, defining the 
pattern of use conferring neurotoxic potential is also challenging. Even with these relaxed criteria, only 
29% reported alcohol use in the preceding 1-year period. (This may reflect cultural aspects of the primary 
demographic).  
 
6.      Triglycerides seem to play a role in pre-ART SDSP. Would it have been better to measure hip waist 
ratio (as in the previous study 2010) rather than BMI to assess for metabolic syndrome, which in 
conjunction with elevated Triglycerides can cause neuropathy? (In previous study BMI was not 
significantly correlated with neuropathy while the hip waist ratio was). Is it possible that ART increased 
triglycerides levels at follow up equally in all patients and therefore evened out the effect of elevated 
triglycerides in SDSP patients pre-ART, which at the time may have been due to co-existing metabolic 
syndrome?  
 
Thank you for this comment. We have included the hip-waist ratio in the table comparing baseline and 24 
month clinical and laboratory findings (we also combined the previously seperate 12- and 24-month 
tables). In the univariate analysis at baseline there was a trend towards an association between SDSP 
and hip-waist ratio, but not for ADSP. Neither showed the association at 24 months. In our previous 
cross-sectional cohort we found similar associations with hip-waist ratio as well as triglycerides and pre-
ART DSP but not in a cross-sectional cohort exposed to ART for a median of 14 months. Although the 
reviewer’s hypothesis is intriguing, we have decided that without enough evidence to suggest any 
postulates we would only highlight these observations when discussing the evolution of two neuropathy 
phenotypes over time. 
 
7.      CD4 counts were assessed at baseline and 24 weeks follow up. I assume treatment 
effect/adherence/developing resistance beyond 6 months follow up is unknown/not assessed. 
 
We did not collect specific data regarding treatment failure or success past 24 weeks. 
 
Study population 
8.      Duration of enrollment (years) would be informative.  
 
A 1.5-year period. We have added to the text. 
 
9.      There was marked loss of follow up of 12% per visit with only 50% assessed at the study endpoint. 
Is this typical for this study population (acknowledging that the patients staying in the study and dropping 
out did not differ in their demographics)?   
 
Some degree of loss-to-follow-up is not atypical in this study population, primarily because of 
socioeconomic factors that drive migration and at times limit access to healthcare. We acknowledge that 
these factors may have introduced bias. Have added text. 
 
Results 
10.     Was the patient’s medication list reviewed which may have included medications for neuropathic 
pain. As a result, use of these medications may explain improvement of pain and paresthesia in the pre-
ART SDSP group after ART initiation, while numbness and physical exam findings did not change. 
(Although I am aware that as stated in previous publication of the group, HIV neuropathy pain responds 
less to commonly used medications and patients are less frequently treated symptomatically in this 
population).  
 
We collected these data, which revealed that a low proportion received therapy for pain, mainly 
amitriptyline: less than 30% for most visits and 50% at the final visit. We have added text to limitations but 
also added that is unlikely to impact on our assessments as amitriptyline is not a useful therapy for HIV 
neuropathy as mentioned.  
 
11.     Improvement of pre-ART SDSP after ART initiation: pain and paresthesia sustainably improved 
after ART initiation, with improvement of pinprick examination at 3 months (although this is not a 
sustained improvement). Vibration sensation, numbness and reflexes did not improve. Could this suggest 
improvement of small fiber qualities rather than large fibers?  
 
We did four longitudinal analyses: 
1) Incidence rate of new SDSP 
2) Survival analysis comparing risk factors for new SDSP 
3) Mean score difference between first occurrence of the abnormality till last follow-up 
4) Prevalence of symptoms and signs at each visit, comparing prevalence at baseline to prevalence 
at follow-up in groups and between groups (pre-ART SDSP vs. pre-ART SDSP-free, stavudine 
vs. no stavudine) 
In analysis 3, pain and paresthesia improved in 50% ever experiencing symptoms, irrespective of DSP 
status. 
In analysis 4, after ART initiation the prevalence of pain and paresthesia decreased in those with pre-ART 
SDSP but without ‘sustained’ improvement in pinprick after 3 months (supplementary fig 4) making it 
difficult to draw a conclusion about small fibers. However, we have expanded the discussion regarding 
the emergence of differences in neuropathic phenotypes at different times within the 2 year period.    
Also, the data suggests that after 18 months of ART, those with SDSP at baseline were not at increased 
risk of developing signs or symptoms compared to those without SDSP at baseline suggesting that the 
early pathogenic process may not be adding to cumulative risk.  
 
12.     Figure 1 compares symptoms and signs of patients with SDSP and SDSP-free patients. Patients 
with ADSP are included in the SDSP-free group. If the SDSP-free group is separated into ADSP and 
neuropathy-free groups, does the effect sustain? Or would this show that patients with ASDP only are 
predisposed to develop worsening of symptoms after ART initiation? This way one could conclude from 
this study that ASDP is a risk factor for new onset of DSDP on ART?  
  
In our survival analysis, we did not find ADSP at baseline to be a significant risk factor for the 
development of SDSP. For the analysis you have suggested, please see comments above. 
The  model for baseline ADSP vs. DSP-free (normal) could not be adequately fitted due to a lack of 
observations at baseline (no symptoms in the ASDP group, no signs in the DSP-free group). We 
substituted a set of dummy observations at baseline which enabled the model to be fitted but resulted 
in inconsistent results and wide confidence intervals for associations. We examined the model for trends 
instead. A greater proportion of those participants with baseline ADSP had painful symptoms at follow-
up visits when compared to baseline DSP-free participants. This difference appeared less prominent for 
the other symptoms. We did not see ADSP at baseline as a predictor for the development of SDSP on 
survival analysis. Signs increased in both groups, but differing profiles were observed for reflexes in the 




Comments to Author: 
1. Please proofread the document and edit for consistency in either British or American English.  As 
pointed out by a reviewer, the text currently mixes both variants.  The journal defaults typically defaults to 
American English. 
 
We have attended to these. 
 
2. Please address the reviewers' comments and questions.  Of particular interest, the discussion should 
address possible differences between small and large nerve fiber response to ART. 
 
Please see above 
 
Editor-in-Chief 
Comments to Author: 
Results 
--Please do not redundantly repeat numbers and percentages in the Results that are provided in the 
tables.  Use Results to highlight important points, and then refer the reader to the Tables for specific data 
when appropriate. 
 
Please see changes in the text. We have retained a few data points in the text particularly from 
supplementary tables. 
 
--Table 1 is rather lengthy, and broad, and thus will be hard for readers to sort through. Can you remove 
those pieces of data that are not critical to your paper?  For example, is it critical for the reader to know 
weight, height, BMI, blood pressure, and cholesterol?  Readers do not need all data, but simply the most 
relevant data.  If you feel you must list all this data, consider moving some to a supplementary table, 
available on-line.  Same concerns about Table 3. 
 
Please see revised Table 1 and 3 and new supplementary tables 1 and 2. 
10) Editorial and issue highlights (Muscle & Nerve) 
 
  
EDITORIAL Muscle Nerve 57: 347–349, 2018
HIV, ANTIRETROVIRALS, AND PERIPHERAL
NEUROPATHY: A MOVING TARGET
MICHELLE KAKU, MD,1 and DAVID M. SIMPSON, MD2
1 Boston University School of Medicine, Department of Neurology, Boston, Massachusetts, USA
2 Icahn School of Medicine at Mount Sinai, Department of Neurology, New York, New York, USA
HIV-distal symmetric polyneuropathy (HIV-DSP) is
the most common neurologic complication of HIV
disease in the post-antiretroviral therapy (ART)
period. There are limited regenerative or symp-
tomatic treatment options for HIV-DSP, and cur-
rently no Food and Drug Administration-approved
therapies exist. Of the ART therapies, dideoxynu-
cleoside analogue ARTs or “d-drugs” such as stavu-
dine, didanosine, and zalcitabine are often vilified
in the HIV-DSP literature. They are known to
cause or exacerbate neuropathy in the HIV popu-
lation and can lead to antiretroviral toxic neuropa-
thy (HIV-ATN).1–4 A previous cross-sectional study
of HIV-infected South Africans found that the fre-
quency of symptomatic HIV-DSP increased from
23% to 40% following ART exposure.5
HIV-DSP and HIV-ATN cannot easily be differen-
tiated clinically or electrophysiologically; develop-
ment of neuropathy symptoms after initiation of
ART may be the only distinguishing factor. Pathophy-
siologically, it is thought that HIV causes neuropathy
directly by the dysregulation of macrophages, release
of pro-inflammatory cytokines, chemokines and free
radicals,6 systemic and cerebrospinal fluid (CSF)
immune activation,7 and neurotoxicity of the gp120
envelope protein.8 In contrast, “d-drug” toxicity is
thought to arise from mitochondrial toxicity caused
by inhibition of gamma DNA polymerase and
reduced mitochondrial DNA content.9 While “d-
drugs” have been largely replaced in developed coun-
tries, they are still used in developing countries and
resource-limited settings. It remains critical to under-
stand the true impact of “d-drugs” versus other ARTs,
the time course of development of HIV-ATN and the
various contributing and potentially modifiable risk
factors for HIV-ATN in this population, given the
prevalence, the limited effective symptomatic thera-
pies, and the impact on quality of life.
In their prospective study that appears in this issue
of Muscle & Nerve, Centner and colleagues studied the
evolution of sensory neuropathy after initiation of
ART therapy in HIV-infected South Africans.10 The
study follows patients at 6-monthly follow up visits for
a 24-month period, beginning before they start. Major
confounders such as pre-existing diabetes, systemic ill-
ness and other comorbid neurological disease were
excluded. They defined symptomatic distal sensory
polyneuropathy (SDSP) as the presence of 1 sensory
symptom (pain, paresthesias, or numbness) with  1
neuropathic sign (reduced pinprick sensation, or
reduced/absent reflexes) and asymptomatic distal
sensory polyneuropathy (ADSP) as the presence of 1
neuropathic sign in the absence of sensory symptoms.
Incident SDSP was defined as asymptomatic at base-
line with development of SDSP after ART initiation.
The authors applied validated tools (Brief Peripheral
Neuropathy Screen and a reduced version of the Total
Neuropathy Score) to assess neuropathy symptoms
and signs.
Of the 184 participants, 16% had SDSP and 39%
had ADSP pre-ART, demonstrating the considerable
prevalence of neuropathy in this population. Pre-
ART SDSP was associated with age, waist:hip ratio,
previous and current TB treatment and higher tri-
glyceride levels. Risk factors independently associ-
ated with baseline SDSP were previous or current
TB treatment and higher triglyceride levels. After 18
months of ART therapy, they found that the preva-
lence of pain symptoms decreased at each follow-up
visit in the baseline SDSP group (odds ratio
[OR] 5 0.09; 95% confidence interval [CI], 0.03–
0.29), while symptom prevalence increased in the
SDSP-free group. The prevalence of signs increased
in the overall cohort at each visit. Participants who
were SDSP-free pre-ART developed incident SDSP
at a rate of 18 per 100 person-years; after 24 months
(n 5 102), 18% had SDSP. In the analysis of partici-
pants receiving stavudine versus a non-stavudine
ART, the researchers found that stavudine did not
predict incident SDSP, but was associated with
increased prevalence of reduced/absent reflexes at
18 months.
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This study provides a unique opportunity to pro-
spectively and longitudinally assess participants
using standardized methods with baseline analyses
before and after initiation of different forms of ART
treatment. Despite the potential risk of developing
HIV-ATN, the present study suggests that the symp-
tomatic benefits of early initiation of ART initiation
(whether “d-drug” or not) outweigh the risk of caus-
ing significant symptoms, as the use of stavudine did
not significantly predict onset of SDSP. Additionally,
the study occurred during the government initiated
phase-out of stavudine and the introduction of
tenofovir-containing ART treatments in South
Africa. Participants who received stavudine had a
higher baseline prevalence of pain and lower
CD4 1 cells counts compared with those who were
started on a non-stavudine containing regimen.
Despite this, symptom prevalence was not signifi-
cantly different between the two groups after treat-
ment initiation. Both groups had an increasing
prevalence of signs but the increase in prevalence
for impaired vibration sensation was significantly
greater in the stavudine group at months 6, 12, and
18 (OR 5 2.24; 95% CI, 1.08–4.65 for stavudine ver-
sus non-stavudine at 18 months).
The discrepancy between increasing signs of
DSP despite decreasing symptoms seen in the over-
all cohort has similarly been demonstrated in a
large cross sectional study of 2,141 HIV-DSP partic-
ipants followed over 7 years, which found that
signs remained in the absence of symptoms despite
virologic and immunologic control with initiation
of combination ARTs.11 Previous studies have dem-
onstrated that markers of systemic and CSF
immune activation are elevated in patients with
ART-naive HIV-DSP compared with HIV patients
without neuropathy.7 Centner and colleagues sug-
gest that viral clearance and immune stabilization
lead to a reduction in painful small-fiber symptoms
seen in participants with pre-existing HIV-associ-
ated SDSP after ART initiation.
The worsening of clinical signs may be due to
slow transport of dysfunctional mitochondria down
axons over months to years and the susceptibility of
distal sensory axons to mitochondrial defects. This
phenomenon warrants further study; the acquisition
of follow up data on the current cohort would be
interesting as a way of determining whether this
trend continues.
Additionally, the authors compare the evolution
of neuropathy in those that were SDSP positive or
negative at baseline. The latter group presumably
includes those that are neuropathy sign-free and
those with ADSP. It would be of interest to compare
evolution of neuropathy (onset of symptoms and/or
onset or increase in signs) in those that are
neuropathy-sign free and those with ADSP at
baseline.
Consistent with previous studies, the authors
found that the first 3–6 months after ART initiation
was associated with the highest risk of developing
SDSP.12 Participants in this study were mostly
women, with a median age of 33. 38% had a history
of previous or current TB treatment, and median
baseline CD4 count was 156. While this CD4 count
may reflect populations in South Africa,13 this rela-
tively advanced immunosuppressed cohort may limit
generalizability of the data to those initiating ART
with a higher CD4 count.
Previously identified risk factors associated with
post-ART HIV-DSP include greater age,11 greater
height,4,11 history of protease inhibitor use,11 his-
tory of statin and fibrate use,14,15 diabetes,11 and
hypertriglyceridemia.15 In the present study, inci-
dent SDSP after ART initiation was associated with
age 40 years (hazard ratio [HR] 5 3.0; 95% CI,
1.5–6.1) and inversely associated with fasting insu-
lin levels (HR 5 0.8; 95% CI, 0.6–1.0).
On multivariate analysis, the association with
fasting insulin remained significant (adjusted
HR 5 0.8; 95% CI, 0.6–1.0), but the association
with age did not. Older age is thought to increase
the vulnerability of peripheral nerves, although the
younger cohort in this study may have impacted
the results. Despite the exclusion of diabetics from
the study, the inverse association with fasting insu-
lin reinforces the link between glucose intolerance
in the HIV population and neuropathy risk. Fast-
ing triglyceride levels were associated with SDSP in
the baseline pre-ART cohort, but were not associ-
ated with SDSP at the end of 24 months.
Previous data suggests that hyper-triglyceridemia
and diabetes, although not necessarily metabolic
syndrome or its components, are associated with
SDSP.16 The authors suggest that the absolute tri-
glyceride level itself may not be critical, but may be
a biomarker for painful neuropathy. In contrast to
studies in developed countries where statin use is
prevalent, this study also had the unique opportu-
nity to assess triglyceride levels in participants not
on statins. Statins are a potential confounder that
are an independent risk factor for HIV-DSP15 and
whose use may decrease the chance of recovery
from symptomatic neuropathy.11
This prospective study demonstrates the trajec-
tory of neurologic signs and symptoms in a young
predominantly female African population with rel-
atively advanced HIV infection, treated with differ-
ent ART therapies. Symptomatic neuropathic pain
mostly improved with ART initiation in the setting
of increasing prevalence of neuropathic signs,
while only a small proportion of the studied popu-
lation developed painful neuropathic symptoms.
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They seem to suggest that initiating ART early,
whether “d-drug” containing regimen or not,
appears to be beneficial from a symptomatic stand
point, particularly if there is no alternative option.
However, in a period where government sponsored
programs are eliminating “d-drugs” in favor of
other ART drugs, the findings raise the question
of whether one should take this risk if and when
other options are available. As the rapid pace of
development and introduction of novel ART con-
tinues, it is critical that neurological benefits and
toxicities be carefully monitored for both the cen-
tral and peripheral nervous systems.
Ethical Publication Statement: We confirm that we have read the
Journal’s position on issues involved in ethical publication and
affirm that this report is consistent with those guidelines.
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Evolution of Sensory Neuropathy after Initiation of Antiretroviral Therapy 
(Page 371)
Individuals infected with human immunodeficiency virus (HIV) may develop a distal sensory polyneuropathy. 
The authors of this study found that patients with such neuropathies had an improvement in painful 
symptoms when treated with anti-retroviral therapy (ART), but that some of those who were neuropathy-free 
prior to ART developed new painful neuropathic symptoms. The accompanying editorial by Drs. Kaku and 
Simpson provides expert perspective for the clinician in the interpretation of these findings. 
Chronic Pain Has a Strong Impact on Quality of Life in Facioscapulohumeral 
Muscular Dystrophy (Page 380)
As is true for many neuromuscular disorders, pain is common in facioscapulohumeral muscular dystrophy 
(FSHD). This study confirmed the common occurrence of pain in FSHD, finding that nearly 90% of individuals 
with FSHD reported pain during the study, more than half reported chronic pain, and nearly a third reported 
chronic, severe pain. Chronic pain had a negative impact on multiple domains of quality of life (QOL). 
Because symptom management is the primary goal of care in patients with FSHD, clinicians should be 
sensitive to the need for adequate treatment of pain as one means of optimizing QOL for these individuals. 
Ventilator-Induced Diaphragmatic Dysfunction in MDX Mice (Page 442)
Patients with Duchenne Muscular Dystrophy (DMD) and some other neuromuscular disorders often are 
treated with intermittent mechanical ventilation, particularly at night. The implications of such treatment for 
diaphragm strength are not understood. Using an animal model of DMD, the authors of this study found 
that diaphragm force loss and biochemical changes in the diaphragm occurred rapidly in response to 
mechanical ventilation. Drs. Smith and Falk, in an accompanying editorial, highlight important differences 
between humans with DMD and MDX mice. They outline the tremendous benefits of noninvasive ventilation 
and some points that require clarification in order to optimize its use.
Feasibility of 7T MRI for Imaging Fascicular Structures of Peripheral Nerves 
(Page 494)
High resolution imaging of peripheral nerves has been critical in framing our thinking about pathophysiology. 
For example, some peripheral nerve lesions that have traditionally been considered compressive, such 
as posterior and anterior interosseous syndromes, appear to arise from processes selectively affecting 
nerve fascicles. This study by Yoon and colleagues features images obtained by 7T MRI that are striking in 
their clarity and detail when compared to conventional 3T MRI studies. Such imaging has the potential to 
transform the diagnosis of peripheral nerve disorders. 
Carpal Tunnel Syndrome in Inherited Neuropathies: A Retrospective Survey 
(Page 388)
Inherited neuropathies are a heterogeneous group of disorders that are commonly seen by neuromuscular 
specialists. Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy. Yet, optimal 
methods for the evaluation and management of CTS in patients with inherited neuropathies have not been 
defined. The authors of this study present data to fill some of these gaps. In this study of patients with CTS 
and inherited neuropathies, CTS was found to be reported at a higher rate than in the general population, 
and the CTS symptom severity score (SSS) was found to be useful for assessing their CTS. Splinting and 
surgery were both found to be associated with significant symptom reduction in these patients as measured 
by the SSS.
Recovery of Rat Muscle Size But Not Function More Than 1 Year After a Single 
Botulinum Toxin Injection (Page 435)
Botulinum toxin is being used with increasing frequency and for longer periods of time in the treatment of 
patients with a wide variety of neuromuscular disorders. In this study, the authors found that rats injected with 
botulinum toxin type A demonstrated persistent muscle weakness a year after injection, despite recovery 
of muscle fiber size and mass. In an accompanying editorial, Dr. Ib Odderson notes that the results of this 
animal study do not seem to parallel the experience of clinicians, who often administer botulinum toxin 
every 3 months to maintain weakness in spastic muscles. He and the authors of the article discuss possible 
explanations. 
11) Data capture instruments
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SA BRIEF PERIPHERAL NEUROPATHY SCREENING/EXAM (UCT REC 221/2008) 
NO: T BASELINE Date: dd mm yy 
We are going to ask you a few questions about sensation in your legs. We will also briefly examine the nerves in your 
arms and legs. We may advise the clinic doctor on treatment.  
BPNS : INSTRUCTIONS FOR RECORDING SYMPTOMS: Ask subject to rate the severity of each symptom in 1a to 1c 
on a scale of 0 (absent) to 10 (most severe) for right and left feet, legs- worst in last week.  Enter the score for each 
symptom in the block marked Severity.  Enter extent of symptoms eg Soles of feet/ toes (TNS=1); up to ankle (TNS=2); 
up to knee (TNS= 3) or above (TNS=4) on the TNS score overleaf. 
1a. Pain, aching, burning in feet or legs. Ingaba iinyawo zakho zibuhlungu, ziyaqagamba, ziyatshisa kangangee-veki 
ezimbini? 
Normal Mild → → → → → → → → Severe 
0 1 2 3 4 5 6 7 8 9 10 
Andinantlungu!  → →  → →   Ndineentlungu ezigqithisileyo! 
1b. “Pins-and-Needles" in feet or legs. Ingaba iinhawo zakho zineenaliti noonotaka kangangee-veki ezimbini? 
Normal Mild → → → → → → → → Severe 
0 1 2 3 4 5 6 7 8 9 10 
Andinantlungu!  → →  →  Ndineentlungu ezigqithisileyo! 
1c. Numbness (lack of feeling) in feet or legs. Ingaba iinyawo zakho zinobundindisholo kangangee-veki ezimbini? 
Normal Mild → → → → → → → → Severe 
0 1 2 3 4 5 6 7 8 9 10 
Andinantlungu!  → →   → →   Ndineentlungu ezigqithisileyo! 
TOTAL SENSORY PRESENCE/SEVERITY SCORE: Obtain the single highest severity score from 1-10 in 1(a - c) above:
0  = Grade 0 1-3 = Grade 1 4- 6 = Grade 2 7-8 = Grade 3 9-10 = Grade 4
Total sensory severity GRADE ____/4 nn4
1d. Does the patient experience leg cramps? Yes (1)  No (0) nn5 
Patient asymptomatic (1a,b,c = 0) 
1e. Has patient had any symptoms in the past which are not currently present? 
Yes (1) No (0) nn6 
Patient symptomatic 
1f. Approximately when did the symptoms start?   Before TB Rx (1) After TB Rx (2) nn7
1g. If symptoms started before TB Rx, then how have the symptoms responded to TB treatment? 
Much Worse (1)  Worse (2)   No change (3)   Better (4) Much Better (5) nn8
1h. Have you taken anything for the symptoms?    Yes (1)     No (0) nn6
1i. If yes, what? _____________________________nn11   How have the symptoms responded? 
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2. INSTRUCTIONS FOR EVALUATING PERCEPTION OF VIBRATION:
Press the 2 ends together of a 128 Hz tuning fork, and release suddenly; place the vibrating tuning fork on the subject’s
clavicle; can they recognise the vibration or “buzzing” (ngcungcazela) of the tuning fork? Repeat and immediately place
the vibrating tuning fork firmly on the interphalangeal bone (not nail) of one great toe and begin counting the seconds.
Subject to tell you when the “buzzing” stops. Repeat on the other side.
Vibration Perception     0- Vibration felt for >10 seconds (normal) 
(Take highest score but both R & L must be abnormal) 1- Vibration felt for 6-10 seconds (mild loss) 
2- Vibration felt for 5 seconds or less (moderate loss)
3- No feeling of vibration (severe loss)
Right  Left 
Great toe interphalangeal bone ____  ____ (2) use highest value______/3 nn11
3. INSTRUCTIONS FOR EVALUATING DEEP TENDON REFLEXES:
With the subject seated, the examiner uses one hand to press upward on the ball of the foot, dorsiflexing the subject’s
ankle to 90 degrees. Using a reflex hammer (long-handled), the examiner strikes the Achilles tendon.
Reflexes 4- Absent
3- Reduced (difficult to elicit)
2- Normal deep tendon reflexes
1- Hyperactive deep tendon reflexes
0- Clonus
Right Left 
Ankle Reflexes:   _____  _____ (3) use highest value____/4 nn12 
(Take highest score but both R & L must be abnormal) 
Final score for BPNS (1+2+3) ____/11 nn13 
Reduced TNS score: tick in the box : 
0 1 2 3 4 
a. Sensory symptoms
from 1a,b,c:  Pain,
burning pins or numbness
none Only in toes or 
soles of feet 
Symptoms extend to 
ankle or wrist 
Symptoms extend to 
knee or elbow 
Symptoms knee or 
elbow or functionally 
disabling 
nn14 
b. Pin sensibility normal 
Reduced in fingers 
/toes 
Reduced up to wrist/ 
ankles 






(use normal as for BPNS)
normal Reduced in fingers 
/toes 
Reduced up to wrist/ 
ankles 





d. Deep tendon jerks
normal Ankle reflexes 
reduced 
Ankle reflexes absent Ankle reflexes absent, 
other reduced 
All reflexes absent nn17 
e. Strength- ankle and
toes plantar & dorsi-
flexion









Final score for rTNS (a+b+c+d+e) ______/20 nn19
Neuropathy classification according to TNS: 
Symptomatic DSP= a ≥1 and b≥1 or c≥1 or d≥1 or significant touch-evoked pain yes/ no ________ n20
Asymptomatic DSP= TNS ≥3  yes/ no ________ nn21
Indeterminate DSP= a ≥1 only  yes/ no ________ nn22
Punch Biopsy performed yes/ no ________ nn23
Examination shows another form of peripheral neuropathy (not symmetric distal sensory) yes/no_____ nn24
refer for further evaluation to neuromuscular HIV clinic at GSH (1st wed am of every month; 404-3209) 
Proprioception in both toes Normal=0  reduced=1  absent=2 ________ nn25
12) Consent form and participant information sheet
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Patient Information Sheet for the McHaart & Neuropathy Study 
Title: Prevalence of HIV Neuropathy and risk factors for antiretroviral toxic neuropathy 
in an HIV positive cohort of Black South Africans. 
Dr J Dave (Endocrinology), A/Prof J Heckmann (Neurology); University of Cape Town 
You are invited to participate in a research project at Groote Schuur Hospital. 
Before you agree to take part you need to understand the following: 
Many HIV-positive patients around the world are treated with a combination of special 
medications to try and stop the HIV from dividing in the cells of the body and causing harm.  
These mediations are called highly active antiretroviral therapy or HAART for short.  
Although HAART cannot cure HIV/AIDS (i.e., some virus still stays in the cells) it has helped 
to fight the development of AIDS and has helped and saved a lot of patients.  However, 
HAART has to be taken for the rest of the person’s life and it has side-effects.  Some of 
these side-effects have included the development of diabetes, cholesterol problems, 
changes in body shape (usually either more or less fat in certain areas of the body) and may 
also damage the nerves in the feet causing pain.  Very little is known about these problems 
in the HIV-patients in South Africa.  In this study we want to monitor the effects of HAART in 
patients in Cape Town and especially in the first year of starting HAART.  This would help the 
doctors and patients to understand the side-effects of HAART, how commonly they occur, 
and how they can best be treated or even prevented.  Not everyone will develop problems on 
HAART but it will be very useful if we can understand who will develop problems so that we 
can try alternative treatment plans. 
One of the possible complications of HIV infection could be damage to the long nerves 
supplying the skin of the feet and legs causing most commonly pain and tingling in the feet. 
This problem is called peripheral neuropathy. Unfortunately, it may also be a side effect of 
HAART (also known as ARVs - anti-retrovirals). Although HAART/ARVs is useful in treating 
HIV, it may also cause or worsen peripheral neuropathy in some patients and very little is 
known about this problem in South African patients. In this study we also want to learn more 
about why some patients with HIV and those taking HAART/ARVs develop painful feet, and 
how treatment for TB and vitamin levels in the body (vitamin B6 especially) can contribute to 
this problem. This will help us to develop ways to prevent or treat this side effect of 
HAART/ARVs.  
We want to study the vitamin B6 levels in the blood and see whether you have enough for 
your body’s needs. We also want to take blood for a genetic test called NAT2 which we think, 
may tell us whether a person’s body needs much more vitamin B6 or not. The NAT2 gene is 
important in inactivating the INH-TB treatment. We think half the general population are “slow 
metabolizers or inactivators” as a result of their NAT2 gene arrangement and that this may 
affect the individual’s need for vitamin B6. “Slow INH inactivators” may need more B6 than 
NAT2 “fast inactivators”  
It is important to realise that not everyone on HAART/ARVs will develop peripheral 
neuropathy, but some individuals are at risk of developing this side effect. It will be useful to 
identify who are at-risk so that we can try and prevent this complication from developing. 
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WHAT WILL HAPPEN IF I AGREE TO PARTICIPATE? 
We will ask you not to eat or drink anything from 10pm the night before your appointment.  At 
your appointment you will be asked to complete a questionnaire and give some basic 
medical information about yourself.  Following this the doctor will examine you (looking 
specifically for changes in your body and any damage to the nerves in your feet) and will 
then insert a drip cannula- this is a small plastic device that stays inside the vein for 2 hours 
allowing all further blood samples to be taken from it without any further need for needle 
pricks.  Blood will then be drawn into a syringe (~ 25 ml, 1 tablespoon) from the cannula.  
After taking the blood sample, you will be asked to drink a glass of water with glucose, a form 
of sugar.  Further blood samples will be taken 30 min and 120 min after taking this sugar 
drink.  The blood will be sent to a laboratory and tested for glucose, insulin, cholesterol, and 
lactate.  Some of the blood will be frozen and kept for testing at a later stage such as the B6 
levels. You will be asked to sign this form to allow us to take some blood for specific gene 
testing such as the NAT2 test; you can either agree to the NAT2 test alone or agree that we 
may store the blood for later genetic testing if we get given permission from the University of 
Cape Town ethics committee to do such a test. Stored blood and genetic samples will not be 
labeled with your personal information. 
Whilst waiting for your blood samples to be taken, the study staff will do the following: a) 
using a tape measure they will measure certain areas of your body including your waist, your 
hips, your height, your upper arm and your thigh, b) take blood pressure measurements c) 
measure your body weight using a scale.  After the blood is taken or at another appointment, 
special X-rays will be organized, called DEXA and CT scans.  These scans are done to 
examine the amount of fat in various areas of your body.  Each test takes less than 30 
minutes to complete.  After your blood tests you will be given some lunch. 
We would then like to follow your progress on HAART over the 1st year of treatment and 
document if you develop any problems or not.  It is very important to see everyone at regular 
intervals- whether you have developed problems or not.  All transport to and from the study 
clinic at Groote Schuur Hospital will be paid by the study.  You will also be given R150 after 
each study visit to compensate you for the day spent at the study clinic.  To make it more 
pleasant for you on the clinic day we will also provide a movie to be watched in the clinic 
lounge area.   
The study staff will also review all of your previous clinic records including all of your previous 
blood test results (including HIV status, viral load, CD4 count, liver function, kidney function, 
etc. 
WHAT ARE THE POSSIBLE DISCOMFORTS OF PARTICIPATING IN THE STUDY? 
Having blood taken will be the only discomfort in this study.  Risk of infection will be 
minimized by using sterile procedures, and all blood samples will be taken by a qualified 
study nurse or doctor. 
WHAT ARE THE POSSIBLE BENEFITS? 
If you are found to have any of the above-mentioned side effects of HAART, then 
arrangements will be made for you to be seen at a hospital where doctors specially trained in 
looking after these problems will look after you.  This study will help doctors find these 
problems early, therefore the required investigation and treatment can be done before any 
further problems arise. 
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DO I HAVE TO PARTICIPATE? 
You do not have to participate in this study.  Your participation is voluntary and if you agree 
to participate then you will be required to sign a form.  You can withdraw from the study at 
any time and this will in no way affect your treatment in the future. 
WILL THE INFORMATION REMAIN CONFIDENTIAL 
Your records will only be viewed by your doctors and people involved in this study, including 
research oversight agencies, which support the rights of subjects involved in research (such 
as ethics committees or the Office of Human Research Protections).  Your details will not be 
made available to anybody not involved in this study.  Although absolute confidentiality 
cannot be guaranteed, the staff involved in this study will strive to keep your records as 
confidential as possible.  All the staff have to sign a confidentiality agreement.   
CONTACT DETAILS OF STUDY STAFF 
Should you have any questions, then please contact the study doctor Dr C Centner or leave 
a message at UCT neurology 021-404-3198.  The UCT Human Research Ethics Committee 
may be contacted at 021-406-6338. 
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Written Informed Consent for the Patient 
Study Number: ..……………….  Patient Initials: …………………………………………… 
I,……………………………………………………………………………………………… 
(Name of patient in block letters) 
Have read and understood all the information given to me about my participation in this study 
and I have been given the opportunity to discuss it and ask questions. I voluntarily agree to 
take part in this study and have received an information sheet outlining the details of this 
study. I understand that I am able to withdraw from this study at any time. 
Please circle if you are willing to give a 20mls (4 teaspoons) of your blood for storage to be 
used by this study and /or at a later date; any further research studies must and will always 
first be cleared by the UCT research ethics committee before the researchers can use your 
blood.  
 I am willing to allow a blood specimen to be stored so that we may measure vitamin
B6 levels at a later stage: YES NO. 
 I am willing to allow a blood specimen for DNA extraction to determine my NAT2
gene status: YES NO. 
 I am willing to allow the left-over DNA to be used for possible future genetic studies IF
the research project has been cleared by the UCT research ethics committee before
the researchers can use my specimen YES NO. 
 I am willing to allow the left-over blood to be used for possible future studies IF the
research project has been cleared by the UCT research ethics committee before the
researchers can use my specimen YES NO 
Signature of patient ……………………………………………  Date …………………… 
……………………………………………. 
Printed Name of Patient 
I have explained the nature and purpose of the study to the patient named above. 
…………………………. ……………………………      ……...…………… 
Signature of doctor Print Name of Doctor      Date 
13) Ethics approval 
  
03 July 2017 
HREC REF: 221/2008 
Prof Jeanine Heckmann 
Neurology 
EB-74, NGSH 
Dear Prof Heckmann 
UNIVERSrrY OF CAPE TOWN
Faculty of Health Science• 
Human Research Ethics Committee 
Room E53-46 Old Main Bulldlng 
Groote Schuur Hoapttal 
Obllervatory 7925 
Telephone [021] 406 6626 
Emall: shyretta,thomas@uct.ac,za 
Web•lte: www. health. uct,ac,za/fhs/resean;;b/hyma neth !cs/forms 
PROJl!CT TITLI!: PREVALl!NCI! OF HIV NEUROPATHV AND RISK FACTORS FOR 
ANTIRETROVIRAL TOXIC NEUROPATHY IN AN HIV POSITIVE COHORT OF BLACK SOUTH 
AFRICANS (MMED CANDIDATE - DR C CENTNER) 
Thank you for submitting your request to the Faculty of Health Sciences Human Research Ethics 
Committee. 
The HREC acknowledge that the MMed candidate Dr Chad Centner will also be Involved In this study. 
Please quote the HREC reference number In all your corre•pondence. 
Yours slncerely {] 
PROFESSOR � BLOCKM 
CHAIRPERSON, FHS HUMAN RESEARCH ETHICS COMMITIEE 
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STYLE
Sources. Webster’s Third New International or
New Collegiate dictionaries (G. & C. Merriam Co.,
Springfield, MA) should be used for spelling and
hyphenation of nonmedical terms, and Dorland’s
Illustrated Medical Dictionary (WB Saunders, Phil-
adelphia) for medical terms. Good sources for gen-
eral style (grammar, punctuation, capitalization,
etc.) are: A Manual of Style (The University of Chi-
cago Press, Chicago) and The Elements of Style, by
Strunk and White (Macmillan Publishing Co., New
York). For units of measure, symbols and nomen-
clature for biochemistry and biology use the CBE
Style Manual (American Institute of Biological Sci-
ences, Arlington, VA) and for medicine, use the
AMA Stylebook and Editorial Manual (American
Medical Association, Chicago).Standard United
States spellings will be used in all publications.
Numbers. Use numerals for all units of mea-
sure and time, and for all enumerations (e.g.,
3 mm, 55%, 2 hours, 9 months, 20 years, 1 of 19
patients). SI unit conversions should appear in
parentheses following all units of measure. Spell
out numbers beginning a sentence.
Abbreviations. Abbreviations should be kept to
a minimum, because their use often confuses read-
ers who are not familiar with the subject matter.
Only standard abbreviations, as listed in the CBE
Style Manual and the AMA Stylebook and Editorial
Manual (see above), may be used without defini-
tion. Terms appearing frequently within a paper
may be abbreviated, but should be spelled out at
first citation, with the abbreviation in parentheses.
The term “MRI’’ for magnetic resonance image is
an exception and need not be spelled out at first
citation.
MANUSCRIPT PREPARATION
 Word format preferred
 Electronic versions in ASCII or PDF are not
acceptable
 Double Space entire manuscript, including refer-
ence section
 Organize manuscript in the following order,
with each component beginning on a separate
page and with a running title and page number
in the upper right hand corner of each page
Title page (page 1)
 Article Title (80 spaces Maximum)
 Authors’ full name (first name, middle ini-
tial, surname) and graduate degree (no
more than 2)
 Author Affiliations (name of department if
any, institution, city and state or country
where work was done) **Authors with
multiple affiliations should provide only
their primary affiliation.
 Acknowledgments if applicable (grant sup-
port and individuals who were of direct
help in preparation of the study
 Number of words in abstract
 Number of words in manuscript (excluding
abstract, references, table titles, and figure
legends).
 Name/address and email address of the
author to whom reprint requests are to be
sent
 Running title (30 spaces Maximum)
 If part or all of the material is contained
within a presentation made at a national
meeting, the organization, city, and date of
the presentation should be included as a
footnote, but details of any abstracts should
not be cited here.
Ethical Publication Statement
 All papers must include the following state-
ment to indicate that the authors have read
the Journal’s Position on Issues Involved in
Ethical Publication and affirm that their
report is consistent with those guidelines:
“We confirm that we have read the Journal’s
position on issues involved in ethical publi-
cation and affirm that this report is consis-
tent with those guidelines.’’
Disclosure of Conflicts of Interest
 One of the following sentences must be
included: either “Author A has received sup-
port from, and/or has served as a paid con-
sultant for . . .. Author B has received support
from. . .. The remaining authors have no con-
flicts of interest.’’ Or “None of the authors
has any conflict of interest to disclose.’’ Note:
Disclosure is needed for financial income/
payment from commercial sources, the inter-
ests of which are relevant to this research
activity. Please identify sources from which
financial assistance/income was obtained
during the period of the research activity and
generation of the current report. Grants
from government and/or private agencies
should be identified in the Acknowledge-
ments section. For additional details see Mus-
cle and Nerve’s Position on Issues Involved in
Ethical Publication below.
Abstract (page 2)
 Include title of article
 No more than 150 words
 Depending on type of article, the
abstract should include sections labeled:
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INSTRUCTIONS FOR AUTHORS
Introduction, Methods, Results, Discussion.
For basic research publications a statement
of clinical relevance is encouraged. Authors
who wish to have additional information
about the structured abstract format are
referred to the National Library of Medicine
website: (http://www.nlm.nih.gov/bsd/poli-
cy/structured_abstracts.html) and to an arti-
cle that reviews the subject: (Harbourt AM,
Knecht LS, Humphreys BL. Structured
abstracts in MEDLINE, 1989-1991. Bull Med
Libr Assoc. 1995;83:190-195).
Key Words
 The authors should provide 5 key words on
the bottom of the abstract page pertaining
to all major points of their contribution.
This will help index the article for reference
citations. Authors are suggested to refer the
below link for adding key words: Search
Engine Optimization: For Authors
Text (starts on page 3)
 Organized in the following format; Intro-
duction, Methods, Results, and Discussion.
Other descriptive headings and subheadings
may be used if appropriate. Every effort
should be made to avoid jargon, to spell
out all nonstandard abbreviations the first
time they are mentioned, and to present
the contents of the study as clearly and as
concisely as possible.
 The methods, apparatus (including manufac-
turer’s name and address), and procedures
should be identified in sufficient detail to
allow other investigators to reproduce the
results. References should be given for all
discussions of previous studies and for all
nonstandard methods used. For experiments
in which humans or animals were studied,
see Muscle and Nerve’s Position on Issues
Involved in Ethical Publication below. For
drugs and chemicals, the generic name
should be used. Patients’ names, initials, or
hospital numbers should not be used.
 Be sure that all references and all tables and
figures are cited within the text. The tables
and figures should be numbered according to
the order in which they appear. Data appear-
ing in tables or figures should be summarized,
not duplicated, in the text. All data cited in
the text should be checked carefully against
the corresponding data in the tables to ensure
that they correspond, and all names cited in
the text should be checked carefully against
the references to ensure that the spelling is
correct. Any ambiguous symbols (e.g., the let-
ter “O’’ versus the numeral “0,’’ the letter “I’’
versus the numeral “1’’) should be identified.
Tables should be of a size that can be printed
in a vertical format on the page, thus the width
should be no more than 6 inches.
Abbreviations
 All abbreviations used in the text should be
listed and defined in alphabetical order on




 Listed and numbered in the order of cita-
tion and number them accordingly.
 Identify references in the text, tables, and
legs by Arabic numerals typed as superscripts.
 Include ALL author names (surnames fol-
lowed by initials, use “et al’’ after the sixth
author in the case of multi-authored works),
 Include the title of the article with the same
spellings and accent marks as in the
original
 Include the journal title abbreviated as it
appears in the Index Medicus or spelled
out if it is not listed there
 Include the date of publication
 Include the volume number
 Include inclusive page numbers.
 For books be sure to include the chapter
title, chapter authors, editors of the book,
title of the book (including volume or edi-
tion number), publisher’s name and loca-
tion, date of publication, and appropriate
page numbers.
 Unpublished observations,’’ “personal com-
munications,’’ and information that has
been obtained from manuscripts “submitted
for publication’’ but not yet accepted
should not appear in the references but
should be cited in parentheses in the text.
Unpublished observations should include
the authors, the year, and should be accom-
panied by letters of permission from all
individuals cited; quotations from manu-
scripts that have been submitted for publica-
tion should include the authors, the title of
the manuscript, and the date. Manuscripts
that have been accepted for publication but
have not yet been published may appear in
the references. Include the authors, manu-
script title, and name of journal, followed
by “to be published’’ in parentheses.
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 Word file, NOT photograph or image files
 If table must exceed 1 typewritten page,
duplicate headings on the second sheet
 Numbered in the order in which they are
cited in the text
 Include a title at top of table
 Every column (including the left-hand
(stub) column should have a heading
 Define all abbreviations immediately below
the table
 Indicate the units of measurements for all
values
 Use commas for all numbers exceeding 999,
and use zeros before decimals for numbers
less than 1
 Organized so that like data are read vertical-
ly, not horizontally.
 Do not use internal horizontal or vertical
lines to separate sections
 Explain all empty spaces or dashes
 Indicate footnotes to the table using the fol-
lowing symbols
 * (asterisk), † (dagger), ‡ (double dag-
ger), § (section mark), (parallels), (par-
agraph mark), # (number sign).
 Letters of the alphabet, lower case and
italic, should be used instead if there
are more than 7 footnotes.
 Symbols (or letters) should appear after
commas and periods, before colons and
semicolons, and should be superscript.
 If data from any other source, published or
unpublished, are used, obtain permission
for their use and cite the source in the
legend.
Figure/Images
 JPEG, TIFF or EPS file format (Tagged
Image File, Encapsulated PostScript)
 Each file must include all subparts (A, B, C,
etc.) to the figure. Subparts should not be
uploaded individually
 Resolution
 Halftones are to be scanned at 300
dots per inch (dpi)
 Line Art is to be scanned at 1200 dpi
 Figures prepared in Word, Excel, Microsoft
Publisher, Lotus 123, PowerPoint and Corel
Draw are not acceptable as digital files
 If your files have been prepared in one of
these formats and cannot be converted you
will be required to mail high quality hard
copy figures.
 All images must be saved and submitted in
final size. The final figure sizes are: 1
column 5 3-in. (8.25-cm) wide, 1.5
column 5 5-in. (13-cm) wide, 2 columns 5 6-
in. (17.15-cm) wide. Figures should not
exceed 8-in. (21.6-cm) in height. All crop-
ping and manipulation must be completed
before the images are submitted to the
publisher.
 Avoid use of fine lines (point and below)
for graphs and charts
 Use only Adobe Type 1 fonts in creating
images, and limit the number for fonts used
 Do not reletter images in Photoshop. If rel-
ettering must be done, import the image
into either Freehand or QuarkXPress and
reletter, then make an EPS file.
 Make sure all scanned images are “clean.’’
Look for and clean up dust specks,
scratches, tape marks, and anything that is
not part of the actual image. Files generated
in Freehand should be saved in EPS format.
 Photomicrographs must include a calibra-
tion bar of appropriate length (e.g., 1mm,
0.1 mm, etc.) Symbols used in micrographs
should contrast with the background.
 For photographs of persons, written permis-
sion from the subject must be supplied.
Article Type Example
Journal Article Franssen H, Straver DC. Pathophysiology of immune-mediated demyelinating neuropathies-
Part II: neurology. Muscle Nerve 2014;17:4–20.
Journal Article
(use et al after 6th author)
Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, et al. POEMS
syndrome: definitions and long-term outcome. Blood 2003;101:2496–2506.
URL Pedersen J, Wallace M. 1999. Wiley Journals DTD: Guidelines for reference tagging.
Available at http://jws-edcd.wiley.com:8255/refguide.html. Accessed February 4, 2002.
DOI Oussalah M. Some notes on fusion of uncertain information. International Journal of Intelligent
Systems 1984;19(6). Published online: April 23, 2004. DOI: 10.1002/int.20001.
Book Smith, J.A. 2001. How to Write Journal Guidelines. Springer: New York
Chapter in a book Katz JN. Developments in surgery for rheumatic and musculoskeletal disorders. In: Pisetsky
DS, editor. The ACR at 75: a diamond jubilee. Hoboken (NJ): Wiley-Blackwell; 2009. p. 87-91.
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Unless specified otherwise, the subject’s
eyes will be masked to prevent
identification.
 Digital Figures. To ensure that your digital
graphics are suitable for print purposes,
please go to RapidInspectorTM at http://rap-
idinspector.cadmus.com/wi/index.jsp . This
free, stand-alone software application will
help you to inspect and verify illustrations
right on your computer.
Figure Legends
 Less than 200 words
 Double spaced
 Numbered with Arabic numerals corre-
sponding to the illustrations.
 When symbols, arrows, numbers, or letters
are used to identify parts of the illustration,
each should be explained clearly in the
legend
 For photomicrographs, the internal scale
markers should be defined and the meth-
ods of staining should be given. If the fig-
ure has been previously published a credit
line should be included
COLOR POLICY:
Figures will be published in color online at no
charge. Authors are required to pay the cost of repro-
ducing color figures in print. Muscle & Nerve charges
per figure, $600 for the first figure. Second, third and
fourth figures are billed at $400 each.
DATA ACCESS
For reports of original data, at least 1 author
(e.g., the corresponding or principal investigator)
is expected to have full access to all the data in the
study and to take responsibility for its accuracy.
Readers are referred to the editorial by Rosenberg
et al. (Muscle Nerve 2002;25:133–134). Such access
must be confirmed on the Author Responsibility
section of the submission site.
Muscle & Nerve’s Position on Issues Involved in
Ethical Publication
(1) Authorship/Credit
Muscle & Nerve follows the guidelines of the Interna-
tional Committee of Medical Journal Editors regard-
ing criteria for authorship (http://www.icmje.org/).
The author list should include those who have made
substantial intellectual/conceptual contributions to
the work. Such contributions should include partici-
pation in: (a) substantial contributions to concep-
tion and design, acquisition of data, or analysis and
interpretation of data; (b) drafting the article or
revising it critically for important intellectual con-
tent; c) final approval of the manuscript version to
be published, and (d) agreement to be accountable
for all aspects of the work. We strongly discourage
the inclusion of “honorary’’ authors (individuals
who are listed as authors but have not contributed to
the work/manuscript - e.g., heads of departments)
and “ghost’’ authorship (individuals who have sub-
stantively contributed to the work and/or manu-
script but are not listed as authors or contributors).
In cases where writing support is necessary, the writ-
er(s) should be acknowledged in the Acknowledge-
ments section, and the source of funding for writing
support should be provided under Disclosure of
Conflicts of Interest. The corresponding/ submit-
ting author must, when submitting a manuscript,
give assurance that all authors have read and
approved the submitted manuscript. The corre-
sponding/ submitting author should also give assur-
ance that all authors have seen and approved the
final (accepted) manuscript, and that the manu-
script includes all conflict of interest declarations.
All individuals who have contributed to the work but
do not meet criteria for authorship should be cited
in the Acknowledgement section.
(2) Funding
Sources of funding (for the research, data analysis,
and manuscript generation) should always be dis-
closed in the Acknowledgements section. Sources
may include government funding agencies, institu-
tions and departments, private industry, and chari-
table organizations and foundations. Funding for
all authors should be acknowledged.
(3) Procedures involving Human and Animal
Subjects
The authors should include within the manuscript an
explicit statement indicating that the submitted study
was approved by the relevant research ethics commit-
tee or institutional review board (IRB), and that
informed consent was obtained from research sub-
jects. When the study involves human participants
(including material from human subjects), authors
should also provide assurance that appropriate con-
sent was obtained. When studies involve animal sub-
jects, authors should provide methodological details
about steps taken to minimize pain/discomfort. Such
papers must contain a statement that affirms that the
experimental protocols were approved by the institu-
tional animal care and use committee (IACUC).
(4) Confidentiality
In all cases, information and images derived from
individual patients must be presented with assur-
ance of appropriate consent and with details
removed that might reveal identity of the individual.
(5) Disclosure
All authors are required to disclose associations
which might affect their ability to present and/ or
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interpret data objectively, particularly financial ties
to funding sources for the work under review (e.g.,
membership on corporate scientific boards, stock
ownership, consultant arrangements, patent owner-
ship or application, etc.). Disclosure of such associ-
ations for the Editorial personnel of Muscle &
Nerve (Editors-in-Chief, Associate Editors, Editorial
Board members) will be published each year.
Reviewers will also be asked to affirm that they
have no conflict of interest when critiquing a
manuscript.
(6) Research Misconduct (Data Fabrication/
Falsification)
Muscle & Nerve will attempt to ensure that any alle-
gations of misconduct are properly investigated. In
the case of any allegations, authors will be given a
right to respond. While the Journal is limited in its
ability to investigate misconduct, we will seek
COPEs (Committee on Publication Ethics) advice
and alert appropriate bodies and encourage them
to investigate.
(7) Plagiarism, Duplication, and Redundant
Publication
Muscle & Nerve requires that work submitted for
publication is the authors’ own work and has not
been misappropriated. When previously published
material is used, appropriate credit must be given
and written permission obtained (for use of copy-
righted material). Muscle & Nerve also explicitly
discourages duplication of published material and
redundant publication. All manuscripts submitted
to Muscle & Nerve are checked with the
iThenticateVR software to detect instances of over-
lapping and similar text. In the case of apparent
or substantial overlap, authors will be asked to
rewrite their article.
(8) Corrections of Erroneous Information
Authors are expected to proof-read their articles
carefully before returning page proofs for publica-
tion. They should make needed corrections at this
time. We recognize that it is only human to err
occasionally, and the Journal is committed to cor-
recting mistakes when those errors affect the inter-
pretation of data or information presented in an
article. Such corrections will be published in the
form of an Erratum, and linked to the original
article electronically. Errors that result from author
oversight in the proofing process, and that do not
affect data interpretation, will not be corrected.
(9) Peer Review
Muscle & Nerve is committed to a peer-review sys-
tem that is fair to the author and enhances the val-
ue of the articles published in the Journal. In
order to encourage qualified reviewers to offer
their time and efforts to the Journal, reviewer
identity is kept confidential. Reviewers are chosen
for their expertise in the field; conflicts of interest
are avoided whenever the Editors are aware of
such issues, and reviewers are asked to affirm that
they have no conflicts of interest in reviewing a giv-
en Muscle & Nerve manuscript. Authors are encour-
aged to identify specific individuals who, they
believe, cannot provide unbiased review.
REVIEW AND PRODUCTION PROCESS
Manuscripts are evaluated by the editor and at
least 2 reviewers, who are informed of the confi-
dential nature of the review process. Decisions of
the editor are final and rejected manuscripts will
not be considered further. All material accepted
for publication is subject to copy editing. Authors
will receive page proofs of their article before pub-
lication, and should answer all queries and careful-
ly check all editorial changes at this stage. Authors
are asked to check for misprints or syntactic errors
and not to otherwise revise the manuscript. The
current policy of Muscle & Nerve calls for an edito-
rial review of all notes added in proof but not
minor modifications made in the text. Any major
alteration that would substantially delay publica-
tion must be approved by the editor, in consulta-
tion with the reviewers, if necessary. Authors are
responsible for the scientific content of their
article.
Accepted Articles
Once a paper is accepted, all files in the final
version of the manuscript will be placed in the
Accepted Articles section of the journal website.
The manuscript files will be in a pdf format. Each
article will include a digital object identifier (DOI)
and a collaborative reference linking service
through which readers can click on a reference
citation and immediately access article content.
Once articles are published electronically, it is not
possible for authors to make further changes
before the print version appears. The print version
will indicate the on-line publication date. This
makes articles available before the print version
and reduces publication time to a few days.
Referrals to the Journal “Brain and Behavior’’
This journal works together with Wiley’s Open
Access Journal, Brain and Behavior, to enable rap-
id publication of good quality research that is
unable to be accepted for publication by our jour-
nal. Authors will be offered the option of having
the paper, along with any related peer reviews,
automatically transferred for consideration by the
Editor of Brain and Behavior. Authors will not
need to reformat or rewrite their manuscript at
this stage, and publication decisions will be made a
short time after the transfer takes place. The
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Editor of Brain and Behavior will accept submis-
sions that report well-conducted research which
reaches the standard acceptable for publication.
Accepted papers can be published rapidly: typically
within 15 days of acceptance. Brain and Behavior
is a Wiley Open Access journal, and article publica-
tion fees apply. For more information please go
to Brain and Behavior.
EarlyView
Once a corrected proof is received by the pub-
lisher from the author and reviewed with the Edi-
tor, individual articles are published on-line in the
EarlyView service maintained by the publisher.
Articles are available as PDF full-text and HTML
full-text.
Wiley: Permissions and Reprints
You can now obtain permission to reproduce
or make copies of Wiley content, for commercial
or non-commercial re-use, directly from the point
of content on Wiley’s websites. For additional
information, please visit http://www.wiley.com/
WileyCDA/Section/id-403426.html
Wiley Online Library
For additional tools visit Author Resources
(http://authorservices.wiley.com/bauthor/default.
asp) - an enhanced suite of online tools for
Wiley journal authors, featuring Article Tracking,
E-mail Publication Alerts and Customized
Research Tools.
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